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Abstract 
Fu, Tingting. M.S.E.. Department of Biomedical, Industrial and Human 
Factors Engineering, Wright State University, 2012. Use of Exploratory Data-
Mining Techniques to Analyze Associations between Bone-Mineral Density and 
Relevant Clinical Parameters of Gaucher Disease.  
 
Gaucher disease (GD) is a monogenic disorder with autosomal recessive 
inheritance, which results from an acid lysosomal hydrolase, the beta-
glucocerebrosidase deficiency. Clinical manifestations of the disease include 
anemia, thrombocytopenia, hepatosplenomegaly, and skeletal complications. 
Enzyme replacement therapy (ERT) has been used to treat type 1 GD for more than 
a decade, and many patients have shown remarkable clinical responses to the 
treatment, with normalization of blood counts, reduction in liver and spleen size, 
and improvement in bone symptoms. Many researchers have tried to study the 
effectiveness of ERT, but previous research has been mainly based on some 
predetermined hypotheses and traditional analysis methods, which assumed some 
statistical distributions of the underlying data. In addition, studies have suggested 
significant individual differences in patients’ bone mineral density (BMD) 
responses to ERT.  
In this project, we used non-parametric regression tree methods to analyze 
the BMD data of patients with type 1 GD, in combination with other potentially 
relevant parameters, including patients’ demographics, hematological, visceral, and 
bone manifestations, to define a parameter subspace that explains the patients’ 
BMD response. Models have been derived for the patient’s initial dual-energy X-
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ray absorptiometry (DXA) Z-score, the rate of change of the patient’s DXA Z-
scores from his/her first infusion to the current DXA assessment visit, and the rate 
of change of the patient’s DXA Z-scores between two consecutive DXA 
assessment visits. Modeling results suggest that the patient’s initial DXA Z-score is 
affected by his/her region, treatment with bisphosphonates, gender, and the period 
between the patient’s first infusion and first DXA visit date. The rate of change of 
the patient’s DXA Z-scores from his/her first infusion to the current DXA 
assessment visit is mostly related to the patient’s’ region, initial DXA Z-score, and 
ethnicity.  In addition, the most predictive covariate of the rate of change of the 
patient’s DXA Z-scores between two consecutive DXA assessment visits is the 
patients’ immediately previous DXA Z-score. 
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I. Introduction 
1.1  What Is Gaucher Disease?  
Gaucher disease (GD) is a monogenic disorder with autosomal recessive 
inheritance which results from an acid lysosomal hydrolase, the beta-
glucocerebrosidase deficiency. Consequently, lysosomes of the reticuloendo-
thelial system accumulate glycolipids, creating engorged macrophages (Gaucher 
cells), which displace normal tissue and result in dysfunction in many organs. 
Clinical manifestations of the disease include anemia, thrombocytopenia, 
hepatosplenomegaly, skeletal complications such as bone pain (BP) and bone 
crisis, cortical and medullary infarctions, cortical bone thinning, medullary 
expansion, osteopenia, osteolysis, osteonecrosis, and pathological fractures (Sim 
et al.,2008). 
Clinically, GD can be classified into three types based on the presence of 
primary central nervous system involvement: type 1 GD is non-neuronopathic 
which is also the most common variant; the rare type 2 GD is neuronopathic; and 
type 3 GD is less common than type 1 GD and characterized by severe 
visceromegaly and variably progressive neurologic involvement (Hans et al., 2008). 
 
1.2  Enzyme Replacement Therapy and Its History 
Enzyme replacement therapy (ERT) is a safe, efficacious treatment for type 1 
GD, which has been used for approximately 15 years. It uses alglucerase and 
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imiglucerase which are useful for treating GD, and patients’ treatment responses 
can be seen within months.  
Before the introduction of ERT, GD patients were mainly treated with blood 
infusion, total or partial splenectomy, and the use of analgesics. In some cases of 
rapidly progressing disease, patients can be treated, but at a high risk, through bone 
marrow transplantation. 
GD was successfully treated with ERT for the first time in the early 1990s, 
using a mannose-terminated enzyme from placental tissue (alglucerase) or a 
recombinant enzyme (imiglucerase, both manufactured by Genzyme, Cambridge, 
MA). Most patients showed a remarkable clinical response to the treatment, with 
normalization of blood counts, reduction in liver and spleen size, and improvement 
in bone symptoms. At the inception of ERT, however, only a few patients could 
afford the therapy because of its prohibitive costs. In order to treat more GD 
patients, the European Cerezyme Access Programme (ECAP) started ERT in 2004. 
 
1.3  Limitations of Previous Research 
Although previous studies of GD have made significant contributions to ERT 
research, they were based on some predetermined hypotheses and applied 
traditional analysis methods, which assume some statistical distributions of the 
underlying data.  In addition, previous studies suggest an indispensable need for 
further research on the effectiveness of ERT on GD-related bone disease, which is 
the most significant cause of immobility and long-term disability for patients. Poll 
et al. (2002) analyzed the lumbar spine bone-mineral density (BMD) measurements 
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of 30 GD patients enrolled in the International Collaborative Gaucher Group 
(ICGG) Gaucher Registry to determine the effect of ERT. Overall, the study found 
significant improvement in the BMD of the patients, yet it also showed significant 
individual differences in the patients’ response to the ERT. In particular, some 
patients showed rapid improvement, but others had only minor improvement in 
BMD even after several years of treatment. Wenstrup et al. (2007) analyzed the 
data of adult patients (men, 18–70 years; women, 18–50 years) enrolled in the 
ICGG Gaucher Registry, for whom lumbar spine BMD measurements were 
available to determine the effect of ERT on BMD in type 1 GD. In the study, the 
sex- and age-specific reference population was first translated to the standardized 
BMD and used to calculate each patient’s the dual-energy X-ray absorptiometry 
(DXA) Z-scores (Hui, 1997). The major steps of the algorithm of Z-scores are: (1) 
subtract the mean BMD from the individual BMD; (2) divide the result by standard 
deviation of BMD.  Their analysis results indicated that the DXA Z-scores for 
patients with GD who received ERT improved significantly over time, approaching 
the reference population.  The authors also noted a significant dose–response 
relationship in the ERT group. Another study led by Genzyme tested BMD 
improvement after ERT in children, adolescents, and adults. A significant dose-
response relationship was noted for each age group, especially for the younger 
patients. However, the study presents very slow recovery, on average, to normal Z-
scores values, which is the average of BMD of a healthy subject of the same age 
and gender. Based on the results of these previous studies, we assume that there 
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may be a combination of variables that can distinguish patients who recover bone 
more quickly under ERT from those who recover bone more slowly. 
 
1.4  Research Objective 
The objective of this research is to use exploratory data mining techniques 
to analyze the BMD data of patients with GD in combination with other potentially 
relevant parameters, including patients’ demographics,  as well as hematological, 
visceral, and bone manifestations, to define a parameter subspace that explains the 
BMD response. 
 
1.5  Data Source of the Study 
Data for this study were retrieved from the ICGG Gaucher Registry, which 
includes patients treated with imiglucerase between the ages of 5 and 50 years.  The 
ICGG Gaucher Registry was first established in 1991 as a voluntary observational 
database to track the clinical, biochemical and therapeutic characteristics of GD 
patients, irrespective of their disease severity and treatment status. It consists of 
international and regional boards of advisors, who oversee the scientific integrity of 
the Gaucher Registry and who guide research, publications, policy, and the 
protocols for the ICGG Gaucher Registry. The ICGG Gaucher Registry is 
composed of anonymous clinical data of 4500 GD patients, which have been 
submitted by over 700 physicians from 52 countries with appropriate Institutional 
Review Board/Ethics Committee approval. 
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1.6  Contribution of the Research 
The significance of the study lies in the fact that it is venturing into using 
previously unexplored non-parametric regression methods to study the effects of 
ERT on treating GD. The models resulted from the study provide valuable insights 
into what demographic and clinical information of GD patients affect their BMD 
responses to the treatment of GD using Imiglucerase.   
 
1.7  Organization of the Thesis 
The roadmap of the thesis is as follows. Chapter 2 reviews previous 
research on the responses of GD-related bone diseases to the ERT, generalized 
linear mixed models (GLMMs), the state-of-the-art modeling technique used in  
previous GD research studies, data mining techniques, and methods of handling 
missing data. The methods of the research are presented in chapters 3 and 4. In 
particular, chapter 3 describes how the raw data retrieved from the ICGG Gaucher 
Registry are preprocessed, and chapter 4 reports how models are derived from the 
preprocessed data and the modeling results. Finally, in chapter 5, the conclusions 
and discussion of the research are offered. 
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II. Literature Review 
2.1  Responses of GD-Related Bone Disease to Enzyme Replacement Therapy  
Many patients with GD suffer progressive and often disabling morbidity 
attributable to skeletal complications, including osteopenia, lytic lesions, 
pathological fractures, avascular necrosis, and joint destruction (Charrow et al., 
2007). Therefore, much effort has been made to study the effectiveness of ERT on 
GD-related bone diseases. 
Elstein et al. (1998) presented a study of examining 28 patients with varying 
disease severity treated with low-dose imiglucerase for 6 to 24 months. The patients 
were divided into two groups in terms of their frequencies of treatment: once every 
other week or 3 times a week. The study did not find any statistically significant 
difference between the two groups in the hematological parameters and 
organomegaly. Although the study did not describe any quantitative data of bone 
responses, it found that all the patients in the study who had GD-related bone 
problems reported subjective decreases in the intensity and frequency of bone crises. 
Analyzing the data of 28 pediatric patients with GD in Italy, USA and 
Germany, Bembi et al. (2002) showed that the lumbar BMD of most of these 
patients significantly increased after 2 years of ERT, and skeletal growth rates 
increased among the patients exhibiting growth delays. This study suggests that 
ERT can improve the BMD and growth rates in pediatric patients with GD.  
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Poll et al. (2002) presented previous studies on the long-term effects of ERT 
from six data sources, with a particular focus on the response of skeletal aspects. 
This study showed a rapid response of bone marrow to ERT. In some patients, 
improvement in bone marrow was detected with MRI within the first year of 
treatment, but this did not reach significance until 4.5 years after starting ERT. 
However, although the dose of ERT may be related to bone marrow response, no 
significant relationship was identified in the study. In addition, the study did not 
find a strong relationship between age, gender, splenectomy status or genotype and 
the response of bone marrow to therapy.  
Weinreb et al. (2002) analyzed data of 1,028 patients with type 1 GD, 
retrieved from the Gaucher Registry, to study 2- to 5-year effects of ERT on 
specific manifestations of GD, including hematologic abnormalities, organomegaly, 
skeletal pain, and bone crises. The study concluded that the ERT can prevent 
progressive manifestations of GD and ameliorate GD associated anemia, 
thrombocytopenia, organomegaly, bone pain, and bone crises.  
Tóth et al. (2003) examined 8 patients (with ages of 3-39 years) with GD 
who underwent ERT for 1-8 years (30-80 IU/kg/bi-weeks/months Ceredase or 
Cerezyme). The study found that the use of ERT in all the patients had led to 
marked improvements in visceral and skeletal pathology of the patients. 
Fost et al. (2006) conducted a retrospective comparative cohort study at 2 
large European treatment centers. A total of 106 adult patients with type 1 GD, who 
started ERT, were divided into 2 groups. One received ERT with an initial dose of 
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no more than 50 U/kg/4 weeks (AMC), and the other received at least 60 U/kg/4 
weeks (HHU). After 12 months of ERT, there were no significant differences 
between the two groups in their increase in platelet count and hemoglobin, and 
decrease in liver volume. However, patients who took the higher-dose treatment 
showed a quicker and better recovery in GD-related bone diseases than those with 
the lower-dose treatment.  
Weinreb et al. (2007) investigated the impact of imiglucerase treatment on 
health-related quality of life (HRQOL) of patients with type 1 GD and bone 
involvement. 32 patients with type 1 GD with skeletal manifestations, including 
bone pain, medullary infarctions, avascular necrosis, and lytic lesions, received 
biweekly imiglucerase (at 60 U/kg), and the short Form-36 Health Survey (SF-36) 
was administered to assess HRQOL. After 2 years of treatment, statistically 
significant improvements were observed for all eight SF-36 subscales. 
In Wenstrup et al. (2007), the BMD data with up to 8 years of follow-up 
were analyzed for 160 patients who received no ERT and 342 patients treated with 
ERT alone. These patients were enrolled in the ICGG Gaucher Registry. The DXA 
Z-scores for the patients who received ERT at a dose of 60 U/kg/2 weeks were 
significantly lower than those of the reference population at baseline, but they 
improved significantly over time. In addition, the study also noted a significant 
dose–response relationship in the ERT group of patients. In particular, the patients 
who received a higher dose of ERT had faster recovery of their BMD.  However, 
the study also found that response to treatment was slower for BMD than for 
hematologic and visceral aspects of GD. 
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Andersson et al. (2008) analyzed data from 884 children in the ICGG 
Gaucher Registry to determine the effects of long-term ERT with alglucerase or 
imiglucerase on hematologic and visceral manifestations, linear growth, and 
skeletal disease. These patients had significant improvement in their BMD Z-score 
and bone crises as well as reduction in their liver volume size and spleen size after 
8 years of treatment.  
With a 48-month longitudinal cohort study of 33 patients with type 1 GD in 
various ethnic groups, Sims et al. (2008) reported decreases in bone pain and 
skeletal complications and increases in the BMD of patients treated with 
imiglucerase. In addition, independent of the patients’ genotype, hematological, and 
visceral status, imiglucerase was shown to be effective for the hematological and 
visceral manifestations of type 1 GD. 
In Mistry et al. (2011) data of 889 patients (with ages ranging from 5 to50 
years) retrieved from the ICGG Gaucher Registry were analyzed. The study found 
improvement in GD–associated diseases, including bone problems. In addition, it 
suggested that the improvement of BMD as a result of ERT may be greater in 
younger patients than in the older adult patients. 
Table 1 summarizes the 11 above reviewed previous studies on the 
responses of GD-related bone disease to ERT, including the main characteristics of 
the research subjects in the studies, the statistical methods used, and their main 
findings.  
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Table 1. Summary of 11 Reviewed Studies on the Responses of GD-Related 
Bone Disease to ERT 
Article 
Key 
Characteristics of 
Research 
Subjects 
Duration 
of ERT 
Statistical 
Analysis 
Method 
Main Findings 
Elstein et 
al. (1998) 28 patients 
6-24 
months 
two 
sample t-
test and 
the non-
parametric 
Mann-
Whitney 
test 
 No statistically 
significant 
difference 
between the two 
groups in the 
hematological 
parameters and 
organomegaly. 
 
Bembi et 
al. (2002) 
28 patients 
Both male and 
female 
 
3-9 years N/A 
 Lumbar BMD of 
most patients 
significantly 
increased after 2 
years of ERT 
 Skeletal growth 
rates increased 
among the 
patients 
exhibiting 
growth delays 
Poll et al. 
(2002) 
More than 2000 
patients from 6 
different data 
sources, Both 
male and female, 
5-78 years old 
9 months 
to  more 
than 8 
years 
N/A 
 Rapid response 
of bone marrow 
to ERT. 
 No strong 
relationship was 
found between 
dose, age, 
gender, 
splenectomy 
status or 
genotype and 
the response of 
bone marrow to 
therapy. 
Weinreb et 
al. (2002) 
1028 registry 
patients from 25 
countries United 
States: 541 (53%) 
2-5 years 
mixed 
model 
repeated-
measures 
ERT can prevent 
progressive 
manifestations of 
GD and 
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Western Europe: 
220 (21%) Israel: 
119 (12%) 
elsewhere: 148 
(14%) 
analysis of 
variance, 
two-
sample t 
tests, chi-
squared 
test, and 
Wilcoxon 
rank sum 
test 
ameliorate GD 
associated 
anemia, 
thrombocytopenia
, organomegaly, 
bone pain, and 
bone crises. 
Tóth et al. 
(2003) 
8 patients, 8-39 
years old,  both 
male and female 
1-8 years 
semi-
quantitativ
e method 
The use of ERT 
in all patients led 
to marked 
improvements in 
visceral and 
skeletal pathology 
of patients with 
Gaucher disease. 
Fost et al. 
(2006) 
Totally 106 
patients 49 
patients, 
Netherlands, 21-
74 years old, both 
male and female  
57 patients, 
Germany,27-82 
years old, both 
male and female 
2-4 years 
Mann-
Whitney U 
test , log-
rank test, 
and chi-
square test 
The patients who 
received higher 
dose of ERT had 
faster recovery of 
their BMD. 
Weinreb et 
al. (2007) 
32 patients,  
less than 70 years 
old 
4 years 
Wilcoxon 
signed-
rank test 
Imiglucerase 
treatment had a 
significant 
positive impact 
on health-related 
quality of life  of 
type 1 GD 
patients with 
skeletal disease, 
including bone 
infarctions, lytic 
lesions, and 
avascular 
necrosis. 
Wenstrup 
et al. 
(2007) 
342 patients,(men, 
18–70 years; 
women, 18–50 
years) 
8 years 
linear 
mixed 
models 
The DXA Z-
scores for the 
patients who 
received the ERT 
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at a dose of 60 
U/kg/2 weeks 
were significantly 
lower than the 
reference 
population at 
baseline, but they 
improved 
significantly over 
time. In addition, 
the study also 
noted a 
significant dose–
response 
relationship in the 
ERT group of 
patients. In 
particular, the 
patients who 
received higher 
dose of ERT had 
faster recovery of 
their BMD.  
However, the 
study also found 
that response to 
the treatment was 
slower for BMD 
than for 
hematologic and 
visceral aspects of 
GD. 
Sims et al. 
(2008) 
33 patients, 10-70 
years old, both 
male and female; 
Ethnicity groups: 
Ashkenazi Jewish 
(23 patients), Non-
Jewish Caucasian 
(6 patients), 
African-
American/Caribbe
an (1 patient), 
Hispanic (2 
patients), 
American Indian 
up to 48 
months 
linear 
mixed 
model 
ERT decreased 
the number of 
bone pain and 
skeletal 
complications and 
increased the 
BMD. Despite the 
patients’ 
genotype, 
hematological, 
and visceral 
status, ERT was 
shown to be 
effective for the 
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(1 patient), others 
(2 patients) 
hematological and 
visceral 
manifestations of 
type 1 GD. 
Andersson 
et al. 
(2008) 
884 patients, 485 
of which are under 
6 years old, 260 
are from 6 to 12 
years old, 93 are 
from 12 to 18 
years old, and 
others' age are 
unknown 
8 years 
linear 
mixed-
effects 
model 
After 8 years of 
ERT, most 
clinical 
parameters 
studied (including 
anemia, platelet 
counts, liver and 
spleen volumes 
and bone crisis) 
became normal or 
nearly normal. 
Mistry et 
al. (2011) 
889 patients, 5-50 
years old, both 
male and female 
over 10 
years 
non-linear 
mixed 
models 
ERT resulted in 
amelioration of 
osteopenia in all 
age groups, with 
the greatest 
improvements in 
younger patients. 
 
 
2.2  Generalized Linear Mixed Model 
Table 1 suggests that the linear mixed model is the most popular statistical 
method used to study the effectiveness of ERT over time. A generalized linear 
mixed model (GLMM) is a parametric linear model for clustered, longitudinal, 
repeated-measures data, which quantifies the relationships between multiple 
predictor variables and a continuous response variable (West et al., 2007). 
GLMMs can be used to analyze clustered data, such as patients in different 
hospitals, and it also can be used in longitudinal or repeated-measures studies in 
which subjects are measured repeatedly in different time periods, conditions, or 
both (West et al., 2007). 
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A GLMM is a model of the form y=Xβ+Zu+e, where y is a vector of the 
continuous dependent variable, X and Z are known design matrixes, β is a vector of 
unknown regression coefficients associated with the X matrix, and u is a vector of 
unknown random effects associated with the Z matrix. The vector of u is assumed 
to be independent and identically distributed (IID), N (0, D). The elements on the 
diagonal of the D matrix represent the variance of each random effect, and the off-
diagonal elements of the D matrix are the covariance between random effects. The 
vector of residuals, e, is assumed to be IID, N (0, R), and each element of the R 
matrix represents the variance of a residual or covariance between two residuals. 
Further, the vectors of random effects and residuals are independent from each 
other. 
Generally speaking, there are two approaches to building GLMMs: the top-
down strategy and the set-up strategy, but the top-down strategy is often used in 
most applications (West et al., 2007). The top-down strategy involves three steps. 
First, we start with a model involving enough fixed effects to explain the mean 
structure. Next, the random effects and residuals are added to the model. Finally, 
we remove from the model the fixed-effect parameters which are not significant. 
After building a GLMM, it is important to carry out model diagnostics to 
check whether the assumptions for the residuals and random effects are satisfied, as 
well as whether the model is sensitive to unusual observations. 
Although the GLMM provides a powerful method to analyze clustered, 
longitudinal and repeated-measures data, it is a rather challenging tool in many 
cases. GLMM makes the analyzing process complex, which may lead to imprecise 
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results. Since the estimation of unknown parameters depends on selected 
model/software, it would make the process subjective.  
The GLMM assumes that random effects and residuals follow multivariate 
normal distributions. However, it is very difficult to check whether the multivariate 
normality assumption is valid or not. 
Moreover, because accurate techniques for estimating GLMM parameters 
are only available in simple cases, complex GLMMs are challenging to fit. 
Therefore, we cannot add too many parameters (fixed-effect and random-effect 
parameters) into the GLMM, which makes this method not suitable in many 
applications (Brooks, 2008). 
 
2.3  Data Mining 
Data mining (DM) is a result of the natural evolution of information 
technology (http://dataminingtools.net/wiki/introduction_to_data_mining.php). A 
broader view of DM considers it as a synonym for Knowledge Discovery in 
Databases, or KDD. A widely accepted definition of KDD was given in Fayyard, 
Piatetsky-Shapiro, and Smyth (1996): KDD is the non-trivial process of identifying 
valid, novel, potentially useful, and ultimately understandable patterns in data. 
Alternatively, others view data mining as simply an essential step in the process of 
knowledge discovery in databases. DM is an iterative process that involves 6 main 
steps: problem understanding, data understanding, data preprocessing, modeling, 
evaluation, and deployment (http://www.dataminingexpertsolutions.com/dm-
process/). 
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For the first two steps, users need to determine their objectives for carrying 
out DM, and collect data that is related to the DM problem. Data preprocessing is 
an extremely important yet often neglected step in DM, whose tasks include data 
cleaning, data reduction and new data construction.  
Modeling is the crucial step in the DM process where some selected data 
mining algorithms are applied to the prepared dataset to extract patterns. Table 2 
summarizes some common techniques used in different DM problems.  After a 
model is built, it is important to evaluate its performance and results with respect to 
predefined objectives. Finally, if all the previous steps are satisfactory and the 
models fulfill the project objectives, the DM results can then be deployed in the 
problem domain. 
  
Table 2. Common Techniques Used to Solve Different DM Problems 
DM Problems Common Techniques 
Data 
Description 
Online Analytical Processing(OLAP), Attribute-Oriented 
Approach, Statistical Approach 
Dependency 
Analysis 
Association Rules, Correlation Analysis, Bayesian 
Networks, Regression Analysis 
Classification 
Decision Trees, Rule Induction, Bayesian Classification, 
Neural Networks, 
K-Nearest Neighbors, Case-Based Reasoning 
Prediction 
Regress Analysis, Regression Trees, Neural Networks, K-
Nearest Neighbors 
Clustering 
K-Means Methods, Hierarchical Methods, Density-Based 
Methods, Neural Networks, Statistical Method, Visualization 
Evolution Trend Analysis, Sequential Pattern Mining, Periodicity 
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Analysis Analysis 
 
 
Decision tree and regression tree are two of the most popular data mining 
algorithms. A decision tree is a method in the form of a tree structure, which 
consists of decision nodes and leaf nodes. All decision nodes have splits, testing the 
values of some functions of their corresponding attributes. Each branch from the 
decision node corresponds to a distinct outcome of the test. Each leaf node has a 
class label attached to it.  A regression tree is an extension of the decision tree 
algorithm to a continuous response variable. The regression result of a leaf node in 
a regression tree can be shown as a single prediction value (usually the sample 
mean of all values of the response variable belonging to the leaf node), or a simple 
function (usually a linear function) that relates the response variable and covariates 
for the cases belonging to the leaf node, or some visual representation of the values 
of the response variable in the leaf node. The tree path of a leaf node in a decision 
tree or regression tree refers to the path of the tree from its root node, the top-level 
node of the tree, which represents the entire dataset, to the leaf node. Each tree path 
can be written in “if-then” condition statements.  
Although varieties of tree algorithms have been developed with different 
capabilities and requirements, most are variations of a core learning algorithm that 
employs a “greedy” top-down search through the space of possible trees. The basic 
procedure is as follows: 
1. Start with the root node which represents the entire training data.  
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2. If all the training data belong to the same class (in a decision tree) or have 
the same values for all the predictor variables (in a regression tree), stop, and the 
node becomes a leaf node. 
3. Otherwise, select the splitting attribute s, which can “best” partition the   
samples based on some goodness measure of splits. This attribute becomes a 
decision node.  
4. A branch is created for each category group of s if s is a categorical 
variable or each interval of s if s is a continuous variable, and the samples are 
partitioned accordingly. 
5. The partition process continues until some tree stopping criterion is 
satisfied, such as the improvement is not substantial enough to justify further 
partitioning or no predictor attribute can be further partitioned. 
   When building a decision tree or regression tree, pruning is an important 
step to obtain a right-sized tree. Generally speaking, there are two strategies of 
pruning (Murthy, 1998): (1) pre-pruning, which avoids creation of more sub-trees 
by restricting the minimum node size, as well as thresholds on impurity and some 
other measures; and (2) post-pruning, which creates an overfitted tree initially and 
then reduces the tree size based on estimated errors. 
Classification and Regression Tree (CART), which was first developed in 
1980s by Breiman et al. (1984), is one of the most well-known tree algorithms. It is 
a nonparametric technique that can select from among a large number of variables 
and their interactions in determining the outcome variable. 
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Instead of employing stopping rules, CART generates a sequence of 
subtrees by first growing a full-grown tree and then pruning it back until only the 
root node is left. Then it uses cross-validation to estimate the misclassification cost 
of each subtree and chooses the one with the lowest estimated cost. In particular, 
CART uses the Gini index to grow a decision tree and uses the sum of squared 
residuals to grow a regression tree. Finally, it uses cross-validation to estimate the 
cost-complexity measure of each sub-tree (a measure combining the error and 
complexity of the subtree) and chooses the one with the minimum cost-complexity. 
In k-fold cross-validation, the original data sample is randomly divided 
into k subsamples. One of the k subsamples is retained as the validation data for 
model testing and evaluation, and the remaining (k – 1) subsamples are used as 
training data for model building. The cross-validation process is then 
repeated k times (the folds), with each of the k subsamples used exactly once as the 
validation data. The results from the k folds then can be combined (e.g. taking the 
average of the k results) to produce a single estimation.  
 
2.4  Missing Data 
Handling missing data is an important issue in this project because many 
records in the original dataset of this project have missing values. This section 
reviews the types of missing data mechanisms and common methods of dealing 
with missing values. 
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The impact of the missing data on the results of statistical analysis depends 
on the mechanism that caused the data to be missing. Generally speaking, there are 
3 types of missing data mechanisms (Little & Rubin, 1987): missing completely at 
random (MCAR), missing at random (MAR) and missing not at random (MNAR). 
MCAR means that the missing data mechanism is unrelated to the values of any 
variables, whether missing or observed. MCAR is a very strong assumption 
because it suggests that missing data values are random samples of all data values.  
MAR is less restrictive than MCAR; it only requires the cause of the missing data 
to be unrelated to the missing values but may be related to the observed values of 
other variables.  In other words, when MAR holds, given observed data, the 
missing mechanism no longer depends on the unobserved data. If the pattern of 
data missingness is non-random and the probabilities of nonresponse depend on the 
missing values themselves, then the missing data are said to be MNAR.  
 
2.5  Methods of Dealing with Missing Data 
Generally speaking, methods of handling missing data can be divided into 2 
broad categories: listwise deletion (discarding the records with missing values) and 
missing data imputation (replacing missing data with estimated values). The first 
one is easy but risky, because it can lose large amounts of information in the study 
unless the incomplete cases comprise only a small fraction of all cases (Roth & 
Switzer, 1995). Therefore, only imputation techniques are reviewed in this section. 
Conventional imputation includes mean imputation, regression imputation, 
and hot-deck imputation methods. Mean imputation, where the missing values of a 
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particular variable are replaced by the mean of the observed values of the variable; 
regression imputation, where missing values are imputed using the prediction from 
a multiple regression analysis; and hot-deck imputation, where missing values are 
replaced by the corresponding values of similar cases. 
 Model-based imputation procedures are advanced imputation methods 
which have gained much attention recently. The basic idea of model-based methods 
is to fit statistical models from observed data and then use the models to predict 
missing values. We review two model-based imputation methods –Maximum 
likelihood estimation and Bayesian imputation in the following paragraphs.  
 
2.5.1 Maximum likelihood (ML) Method of Handing Missing Data  
Maximum-likelihood (ML) estimation is a method of estimating parameters 
in a statistical model, which also can be used in an incomplete dataset (Paul et al., 
2003). 
Before discussing the ML method of treating missing data, we will review 
some basic principles of ML estimates first. 
Generally speaking, the basic principle of the ML method is to maximize 
the estimate of parameters, given statistical models and related data. More 
specifically, if we want to estimate a parameter θ, under the assumption that all 
observations are identically independently distributed (IID), the likelihood for the 
sample with n observations is  
L ( ) =∏        
 
   , 
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          where Π is a symbol for repeated multiplications.  
From the equation above, θ is a set of unknown parameters that drive   . 
The problem then becomes to selects the values of the model parameters that 
maximize the probability of the observed data. In practice, it is common to work 
with the logarithm of L(θ), or ln(L(θ)), called the log-likelihood. 
ML also can deal with incomplete-data in a similar way. For example, we 
plan to collect data on two variables, x and y, given a sample of n independent 
observations. For the first m observations, we can get data of both x and y variables; 
for the n-m observations, variable x is missing data and we only collect the data of 
variable y. For the observations with complete data, we present the likelihood by f 
(      , where   is a set of unknown parameters that drive the distribution of x and 
y. Assume x is continuous, the likelihood for entire sample is like: 
L ( ) =∏           
 
   ∏        
 
     ; 
Of the many ways to obtain maximum likelihood estimators, the 
Expectation-Maximization (EM) algorithm is a very general method for estimating 
the parameters with missing data (Paul et al., 2001). It also can be used to obtain 
unbiased predictions for the missing values by parameters of the data model. As its 
name mentioned, Expectation indicates computing expected value of complete data, 
given observed data; maximization is maximizing the resulting function to obtain 
unknown parameters.  
The process can be divided into 3 steps:  first, one should estimate the 
unknown parameters, that is, the variance, covariance and means based on 
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complete data (m observations) and use them to build statistical models; then 
compute the missing values based on the statistical models. After all the missing 
values have been imputed, the new values of unknown parameters can be obtained 
by maximizing the probability of the entire dataset.  
2.5.2 Bayesian Method of Treating Missing Data 
An alternative approach of imputing missing data is called Bayesian method, 
which is widely used in dealing with categorical missing data. Bayesian 
computation in a missing data problem is based on the joint posterior distribution of 
parameters and missing data, given model assumptions and observed data. 
In the Bayesian method, the estimate of distribution of the parameter θ can 
be made in terms of a probability statement, which is expressed as p(θ| y), and y is 
observed value. The joint probability distribution of θ and y can be expressed as a 
product of the prior distribution p (θ) and sampling distribution p(y|θ), respectively: 
p (θ, y) = p (θ) p(y|θ). Based on Bayes’ rule, the posterior density is                         
p (    ) =
      
    
 
           
    
. Since y indicates observed data, p(y) can be seen as a 
constant, yielding the posterior density as p (θ |y) ∝ p (θ) p (y|θ). 
Chen and Astebro (2003) proposed an easy-to-implement Bayesian model-
based approach to imputing missing categorical data, assuming the missing data 
mechanism is MCAR or MAR. If the missing data mechanism is MCAR, then we 
use the following procedure to impute missing data, under the assumption that the 
sampling model is a multinomial distribution with the parameter θ, and    =p(X=i, 
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Y=j|θ). If the missing data mechanism is MAR, we divide the value of X into r 
groups based on the values of X (X=1, 2… r) and classify observed Y into these 
groups. Then, we use the following procedure to impute missing data in each of 
these groups. 
1.   For a categorical variable Y with k possible outcomes, calculate the point 
estimate for the probability of each outcome j using the formula: 
     =
    
   
, where    is the number of observations in the data for outcome j,                                                
and n is the total number of observations for variable Y.               
2. Compute   =∑   
 
   for all j where and j=1 to k. Note that   =1. 
3. For any observation i with a missing value, draw a random value,    from 
the range [0, 1). If 0       , replace the missing value with outcome 1; if 
        , replace the missing value with outcome 2; …; if         , replace 
the missing value with outcome k. 
4. Repeat step 3 for all missing observations of the variable. 
5. Repeat steps 1 through 4 for all other categorical variables with missing 
data satisfying MCAR to form a complete data set. 
 
2.5.3 Multiple Imputations 
The imputation methods that only one value is filled for each missing data 
point are called single imputation. Although they are strong techniques, single 
imputations cannot reflect the sampling variability in the actual values of the 
missing data under one model for non-response (Little & Rubin, 1987). Fortunately, 
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there is another alternative approach—multiple imputations (MI), which can 
remove these limitations. 
Multiple imputations, was first proposed by Rubin in the early 1970’s as a 
way to address missing data. Different from single imputation, where only one 
value is filled for each missing data point, multiple imputation indicates replacing 
each missing value by more than one imputed data.   
Generally speaking, there are three main steps involved in multiple 
imputations (Paul et al., 2001). First, we repeat the imputation procedure more than 
once, producing multiple complete data sets. Second, each of these complete data 
sets is analyzed using standard analysis procedures. Third, the results from these 
complete data sets are combined for inference. 
Rubin (1987) showed that the efficiency of an estimate based on m 
imputations,             ,where λ is the percentage of missing information. For 
instance, with 20% missing information, m = 4 imputations can achieve bout 95% 
efficiency.   
 
III. Data Preprocessing 
Two main phases are involved in this research: data preprocessing and 
model development. This chapter focuses on the first phase of the research, 
describing how the raw data retrieved from the ICGG Gaucher Registry are 
preprocessed before model development.  
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Data preprocessing is an important yet often neglected step in data mining, 
which includes data cleaning, data reduction, new data construction and data 
formatting.  Data cleaning is necessary when dealing with incomplete, noisy and 
inconsistent data. The purpose of data reduction is to obtain a reduced dataset 
which is smaller yet contains most of the important information of the complete 
dataset. New data construction includes tasks such as generating new attributes 
and records, merging tables, and transforming data. Data formatting involves 
syntactic modifications to the data without changing its meaning. This step may 
be necessary for some particular modeling tools used in the next phase of model 
development.  
 
3.1  Summary of Variables in the Raw Data 
The data set from the ICGG Gaucher Registry includes 889 patients and 
45 variables. Those variables can be divided into three categories based on their 
features. The first category includes 27 variables related to the patients’ 
demographics and characteristics. The second category contains 8 variables 
related to the patients’ hematological and visceral manifestations at their first 
infusion of imiglucerase. The remaining 10 variables are related to the patients’ 
bone manifestations at their first infusion of imiglucerase. Tables 3 – 5 summarize 
meaning, type, value, and the number of missing values of each variable in the 
three categories, respectively. 
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Table 3. Variables Related to Each Patient’s Demographics and Characteristics 
Variable Meaning Type and values 
Missing 
values 
REG_ID_N patient identification 
categorical (unique ID for 
each patient) 
0 
AGEINF 
patient’s age at first infusion (in 
year) 
continuous 0 
INFUSDT date of the first enzyme infusion date-time 0 
VISITDT date of a DXA assessment visit date-time 0 
BISPHOS 
whether the patient had 
treatment with bisphosphonates 
binary (yes/no) 0 
STARTDT 
date of the treatment with 
bisphosphonates 
date-time 0 
YRSFUP 
years between the first infusion 
and each DXA visit date 
continuous 0 
SEX gender binary(male/female) 0 
ETHGRP patient’s ethnicity group 
categorical (African-
American; American-
India; Asian; Caucasian; 
Hispanic; Jewish-
Ashkenazi; Jewish-Both 
Ashkenzi and Sephardic; 
Jewish-Neither Ashkenzi 
or Sephardic; Jewish-
Sephardic; Multi-Ethnic) 
95 patients 
(10.7%) 
REGION patient’s geographic region 
categorical (Americas; 
Asia, Pacific, S.Africa; 
Europe; Middle East; 
USA) 
0 
GEN370S patient’s genotype 
categorical 
(N370S/N370S;N370S/Ot
her; Other/Other) 
117 
patients 
(13.2%) 
SPLSTAT patient’s splenectomy status 
binary (never/ever 
splenectomized) 
1 patient 
(0.1%) 
SPLDT date of splenectomy date-time 
1 patient 
(0.1%) 
DOSE3Y 
average dose of imiglucerase (in 
U/kg/2wks) 
continuous 
24 patients 
(2.7%) 
SPINEZ lumbar spine DXA Z-score continuous 0 
DXASP2 
whether a patient had more than 
one DXA assessment visit 
binary(yes/no) 0 
BSPINEZ 
whether a patient had a record 
of baseline spine DXA score 
binary(yes/no) 0 
BSPINEZ1 
whether a patient's baseline 
spine DXA Z-score is equal to 
or below -1 
binary(yes/no) 0 
APTOTYP lumbar vertebrae total type categorical (L1-L4;L2-L4) 
5 patients 
(0.6%) 
SPINETOT lumbar vertebrae total L1 type continuous 
31 patients 
(3.5%) 
DEXAMACH measurement device 
categorical (Hologic; 
Lunar) 
98 patients 
(11.0%) 
AGEGRP1 whether a patient’s age is ≥5 to binary (yes/no) 0 
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<12 
AGEGRP2 
whether a patient’s age is ≥12 to 
<20 
binary (yes/no) 0 
AGEGRP3 
whether a patient’s age is ≥20 to 
<30 
binary (yes/no) 0 
AGEGRP4 
whether a patient’s age is ≥30 to 
<50 
binary (yes/no) 0 
BMIB 
a patient’s body mass index at 
baseline 
continuous 
292 
patients 
(32.8%) 
 
 
 
Table 4. Variables Related to Patients’ Hematological and Visceral Manifestations 
Variable Meaning Type and Value 
Missing 
Values 
HGB hemoglobin(G/DL) continuous 
204 patients 
(22.9%) 
ANEM whether a person has anemia binary (yes/no) 
204 patients 
(22.7%) 
PLT platelet count(×10^3/mm^3) continuous 
204 patients 
(22.7%) 
THROM 
thrombocytopenia category 
categorical (none/mild; 
moderate; severe) 
202 patients 
(22.7%) 
SPLENO splenomegaly category 
categorical (none/mild; 
moderate; severe) 
496 patients 
(55.8%) 
SPLMN 
spleen volume(multiples of 
normal) 
integer 
496 patients 
(55.8%) 
HEPATO hepatomegaly category 
categorical (none/mild; 
moderate; severe) 
493 patients 
(47.6%) 
LIVMIN liver volume (multiple of normal) integer 
493 patients 
(47.6%) 
 
 
Table 5. Variables Related to Patients’ Bone Manifestations 
Variable Meaning Type and Value Missing Values 
INFARC presence of  infraction binary(yes/no) 
603 patients 
(67.8%) 
EFD 
presence of  erlenmeyer flask 
deformity 
binary(yes/no) 
565 patients 
(63.6%) 
AVN presence of  avascular necrosis binary(yes/no) 
572 patients 
(64.3%) 
MARR presence of  marrow infiltration binary(yes/no) 
525 patients 
(59.1%) 
FRACT presence of  fractures binary(yes/no) 
702 patients 
(79%) 
LYTIC presence of  lytic lesions binary(yes/no) 
702 patients 
(79%) 
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OSTEO presence of  osteopenia binary(yes/no) 
633 patients 
(71.2%) 
BPAINPM 
presence of  bone pain during 
past month 
binary(yes/no) 
251 patients 
(28.2%) 
BPAINSEV levels of bone pain severity 
categorical(very 
mild, mild, 
moderate, severe, 
extreme) 
711 patients 
(80.0%) 
BCRISLS 
presence of  bone crises since 
last submission 
binary(yes/no) 
471 patients 
(46.9%) 
 
3.2  Imputation of Missing Data 
As shown in Tables 3 – 5, most variables in the raw data set have missing 
values. Therefore, we need to decide how to handle the missing data before model 
development. In this study, we imputed the missing values for three variables of 
patients’ demographics and characteristics which are considered important potential 
predictive variables for model development. They are ETHGRP, DOS3Y, and 
BMIB. 
In particular, we used the maximum likelihood (ML) method, which we 
mentioned in chapter 2, to impute missing values of DOSE3Y based on REGION, 
SEX, AGEINF, and SPINEZ at the patient’s first DXA assessment visit, and 
impute the missing values of BMIB based on ETHGRP, SEX, and AGEINF. 
Although the ML based imputation method is powerful, it also has 
limitations. Because the ML method assumes that the variables involved are 
normally distributed, it cannot handle categorical variables effectively. Therefore, 
we used an alternative approach—Bayesian imputation to impute the missing 
values of ETHGRP based on REGION and GEN370S. 
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 Because ETHGRP and BMIB have relatively high missing rates – 10.7% 
and 32.8%, respectively, we carried out multiple imputations for them. Based on 
the formula of multiple imputations  described in chapter 2,            , where λ 
is the percentage of missing information and m is the number of imputations, we 
imputed ETHGRP twice and BMIB six times in order to achieve about 95% 
efficiency in their estimates.  
 
3.3  New Variable Construction 
Although imputation is a good method of handling missing data, it cannot 
handle variables with too many missing values, such as the variables related to the 
patient’s hematological, visceral, and bone manifestations shown in Table1. In 
order to solve this problem, we constructed 11 new variables based on the original 
variables, as summarized in Table 6.  
 
Table 6.  Summary of Constructed New Variables 
 
New Variables Meaning Type 
SPINEZ_FIRST 
the patient’s DXA Z-score at his/her first DXA 
assessment visit 
numeric 
BIWEEK_FIRST_VISIT 
the number of bi-weeks between the patient’s first 
infusion and first DXA visit date 
numeric 
BIWEEK_FOLLOW_VISIT 
the number of bi-weeks between the patient’s first 
DXA assessment visit and each of his/her follow-up 
DXA assessment visits 
numeric 
BIWEEK_CONVISIT 
the number of bi-weeks between the patient’s 
consecutive visits 
numeric 
RATE_SPINEZ 
the rate of change of the patient’s DXA Z-score from 
his/her immediately previous visit to the current 
visit, calculated as the patient’s DXA Z-score in the 
current visit subtracted from that in his/her 
immediately previous visit, and then divided by the 
number of bi-weeks between the two consecutive 
visits (only if the patient had multiple visits) 
numeric 
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FIRST_RATE_SPINEZ 
the rate of change of the patient’s DXA Z-score from 
his/her first infusion to current visit 
numeric 
PREVIOUS_SPINEZ 
the DXA Z-score in each patient’s immediately 
previous DXA assessment visit 
numeric 
THROM_HEPATO 
Combine THROM and HEPATO to see how many 
of them were categorized as "severe". 
non-
negative 
Integer(0
, 1, 2) 
SPLSTAT_SPLENO 
Combine SPLSTAT and SPLENO to see whether 
SPLSTAT is “ever splenectomized” or SPLENO is 
“severe”. If so, SPLSTAT_SPLENO is assigned as 
“severe”, otherwise, it is “not severe” 
binary 
(severe/n
ot 
severe) 
BONE_PROBLEMS 
Combine INFARC, EFD, AVN, MARR, FRACT, 
LYTIC, and OSTEO to see how many of these 
variables were reported as “yes” for a patient. 
non-
negative 
Integer 
(0,1,2,3,
4,5,6,7) 
BONE_PAIN 
Combine BPAINPM, BPAINSEV, and BCRISLS to 
see whether a patient’s BPAINPM was recorded as 
“yes” and BPAINSEV as "severe" or “extreme”, or 
BCRISLS was recorded as “yes”; if so, 
BONE_PAIN was assigned “yes”,  otherwise, “no”. 
binary(y
es/no) 
 
3.4 Distributions of Selected Variables 
In this section, we present the distributions of 13 variables. These variables 
are AGEINF, BISPHOS, SEX, ETHGRP, REGION, DOSE3Y, SPINEZ_FIRST, 
BMIB, BIWEEK_FIRST_VISIT, BIWEEK_FOLLOW_VISIT, 
BIWEEK_CONVISIT, FIRST_RATE_SPINEZ, and RATE_SPINEZ. For 
ETHGRP, DOSE3Y and BMIB, because we have imputed their missing values, 
their distributions before and after the imputations are both illustrated in this 
section. 
Figure 1 illustrates the distribution of AGEINF. From this figure, we can 
see the largest age group in the data set was between 5 and 10 years old. Figure 2 
illustrates the distribution of BISPHOS, which shows most patients (750 out of 891 
patients) did not have treatment with bisphosphonates. Figure 3 illustrates the 
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distribution of SEX, which shows that there were more female (594 out of 891 
patients) than male patients. Figure 4 illustrates the distribution of REGION, which 
shows that most patients were from the USA (452 of 891 patients), followed by 
Europe (214 of 891 patients), the Middle East (107 of 891 patients), the Americas 
(102 of 891 patients) and Asia, Pacific and South Africa (16 of 891 patients).  
 
                              
      
 
                                                                    
                           
 
Figure 1. Histogram of AGEINF                                   Figure 2. Histogram of BISPHOS 
Figure 3. Histogram of SEX Figure 4. Histogram of REGION 
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Figure 5(a) shows the distribution of ETHGRP with missing data. We can 
see that the two largest ethnic groups were Caucasian and Jewish Ashkenazi, which 
together accounted for about 80% of all the patients, followed by Hispanic and 
African American, which accounted for about 5% and 4% of the total number of 
patients, respectively. Each of the remaining groups had less than 1% of all the 
patients.  
Figures 5(b) and (c) illustrate the distributions of ETHGRP after the 1
st
 and 
2
nd
 imputations, respectively. We can see their distributions are very similar to the 
distribution before imputation (Figure 4); they also show that more than 80% of the 
patients were Ashkenazi Jewish and Caucasian. 
 
 
                      
 
Figure 5 (a). Histogram of ETHGRP before Imputation 
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Figures 6(a) and (b) illustrate the distributions of DOSE3Y before and after 
imputation, respectively.  They both indicate that most patients’ dosages were 
between 50 and 60 U/kg/2wks, between 20 and 30 U/kg/2wks, and between 10 and 
20 U/kg/2wks.  
                                
                     
        
                                                                                                                                    
Figure 5 (b). Histogram of ETHGRP 
after the 1
st
 Imputation 
Figure 5 (c). Histogram of ETHGRP 
after the 2
nd
 Imputation 
Figure 6(a). Histogram of DOSE3Y 
before Imputation 
Figure 6(b). Histogram of DOSE3Y            
after Imputation 
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Figure 7(a) illustrates the distribution of BMIB with missing data. We can 
see that the BMIB values of most patients ranged between 10 and 30. Figures 7(b) 
and 7(c) illustrate the distributions of BMIB after the 1
st
 and 2
nd
 imputations, 
respectively. In total, there are 12 imputations (2 imputations of ETHGRP × 6 
imputations of BMIB) of missing data. Since all of their distributions are very 
similar, only two of them are illustrated here. Comparing Figures 7(a), (b), and (c), 
we can see that some of the imputed values of BMIB are below 10 whereas the 
original BMIB values were always greater than 10. However, all 3 figures show 
that most patients’ BMIB values fell between 10 and 30.  
 
               
                                               
 
 
Figure 7(a). Histogram of BMIB before Imputation 
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Figure 8 illustrates the distribution of BIWEEK_FIRST_VISIT, which 
suggests that the first DXA assessment visits of most patients occurred within 250 
bi-weeks after their initial infusions. Negative values of BIWEEK_FIRST_VISIT 
mean that the first DXA assessment visits of some patients occurred before their 
initial infusions. 
Figure 8 illustrates the distribution of BIWEEK_FOLLOW_VISIT, which 
shows us that the most follow-up DXA assessment visits occurred within 250 bi-
weeks of the first assessment visit, especially during the first 150 bi-weeks.  
Figure 9 illustrates the distribution of BIWEEK_COVISIT, from which we 
can see most time intervals between a patient’s two consecutive visits were less 
than 50 bi-weeks, followed by between 50 and 100 bi-weeks, and between 100 and 
150 bi-weeks. Very few time intervals were greater than 150 bi-weeks.  
 
Figure 7(b). Histogram of BMIB after 
1
st
 Imputation 
Figure 7(c). Histogram of BMIB after 
2
nd
 Imputation 
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Figure 11 illustrates the distribution of SPINEZ_FIRST, which 
approximates a normal distribution, with most values ranging between -2 and 0.  
Figure 8. Histogram of 
BIWEEK_FIRST_VISIT    
Figure 9. Histogram of 
BIWEEK_FOLLOW_VISIT           
Figure 10. Histogram of BIWEEK_COVISIT 
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Figure 12 illustrates the distribution of FIRST_RATE_SPINEZ, which 
suggests that most rates of change of a patient’s DXA Z-score from that of the first 
DXA assessment visit were between -0.1 and 0.1. 
Figure 13 illustrates the distribution of RATE_SPINEZ, which demonstrates 
a similar pattern as that in Figure 12, with most values ranging from -0.1 to 0.1, 
 
                
           
             
 
               
 
Figure 11. Histogram of 
SPINEZ_FIRST                
Figure 12.  Histogram of 
FIRST_RATE_SPINEZ           
Figure 13. Histogram of RATE_SPINEZ 
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IV. Model Development 
In this project, we focus on building models for three response variables by 
using the regression tree method: SPINEZ_FIRST, which represents a patient’s 
DXA Z-score at his/her first DXA assessment visit, FIRST_RATE_SPINEZ, which 
is the rate of change of the patient’s DXA Z-score from his/her first infusion to the 
current DXA assessment visit, and RATE_SPINEZ, which refers to the rate of 
change of the patient’s DXA Z-score between two consecutive DXA assessment 
visits. For each response variable, models have been derived from the 12 complete 
datasets with imputed missing values, as described in chapter 3 of the thesis, as 
well as from the original data set with missing values. 
 
4.1  Regression Tree Method  
Regression tree methods are used in this research to derive models from the 
preprocessed data thanks to the two main advantages of regression trees over 
traditional regression methods. First, it is very easy to interpret the results of a 
regression tree model, because the final results of a regression model can be 
summarized in a series of logical “if-then” conditions. Second, regression trees are 
nonparametric and nonlinear, making no implicit assumption about the underlying 
relationship between the response variable and covariates.  
In particular, two regression tree algorithms with different approaches to 
selecting the splitting covariate and stopping criteria are applied in this project. The 
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first algorithm is the RPART package in R (Atkinson et al., 2000), which 
implements many of the ideas of CART. The other algorithm is the PARTY 
package in R, which selects the splitting criteria based on the theory of permutation 
test and conditional distribution of statistics.  
4.1.1 RPART Package 
In RPART, the splitting attribute,    
 , is selected based on minimization of 
expected sum of variances for two resulting nodes, as shown in Equation 1:  
arg min                 [  var (  ) +   var (  )]                                   (1) 
                         ≤  
 , j=1,..., M 
where    and   represent the probabilities of cases in the left and right 
nodes, respectively. var (  )  and var (  ) represent the variances of response 
variable Y in the left and right child nodes, respectively.  This splitting criterion is 
equivalent to maximizing the between-group sum-of-squares and minimizing the 
within-group sum-of-squares in the analysis of variance (ANOVA).   
Like CART, RPART uses the cost-complexity function to select the best 
tree size. Given a tree T with |T| leaf nodes T1, T2… T|T| and the cost of adding one 
more leaf node into the model α, the cost of T is defined as follows: 
                                                                           (2) 
where  
R(T) = risk of T = ∑           
   
                      (3) 
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in which P(Ti) and R(Ti) represent the probability and risk of leaf node Ti, 
respectively. By these definitions, selecting a tree with the “optimal” size is finding 
the smallest tree T for which Rα (T) is minimized. Cross-validation is used to 
choose the best value for α.   
4.1.2 PARTY Package 
Like most regression tree algorithms, RPART has a selection bias towards 
covariates with many possible splits. The “ctree” routine in the PARTY package 
addresses this problem by separating the selection of splitting covariates and 
splitting points of the covariates into two distinct steps at each iteration of the tree 
construction.  Measuring the association between covariates and the response 
variable by conditional distribution of statistics is the basis for unbiased selection 
among covariates measured at different scales (Hothorn et al, 2006).  
Given the responsible variable Y and m covariates (       ), the 
conditional distribution Y given X is: 
D (Y|X) =D (Y|       )    (4) 
To test whether there is dependency between Y and Xj (j = 1, 2… m), the 
null hypothesis is 
  
 
: D(Y|  )=D(Y),     (5) 
        The global null hypothesis is 
  =    
   
 
,      (6) 
If    cannot be rejected at a pre-specified significance level α, the recursion 
of the tree is stopped.  Otherwise, the covariate with the strongest association to Y 
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is selected as the splitting covariate. The association between Y and   (j=1… m) is 
measured by a form of linear statistics: 
  (  , w)=vec(∑   
 
     (   )               
 ) (7) 
 where     is the case weight of i,     is a non-random transformation of the 
covariate   , h is the influence function, a non-random transformation of Y. 
Selection of    and h depends on the distributions of    and Y. The distribution of 
  (  , w) depends on the joint distribution of Y and   . 
To find the distribution of   (  , w), permutation tests on each possible 
permutation of the response, S (  , w) are used. The conditional expectation    and 
covariance ∑   are: 
  =E (  (  , w)| S (  , w))    (8) 
∑  =V (  (  , w)| S (  , w))    (9) 
Then, we calculate the p-value of the conditional test for   
 
 on each 
covariate. If the minimum of the p-values is less than a pre-specified nominal level 
α,    is rejected, and the covariate with the minimum p-value is selected as a 
splitting attribute. Test of the global hypothesis    can be based on univariate p-
values or multiple test procedures such as Bonferroni-adjusted p-values and the 
min-p-value resampling approach. 
After the splitting covariate     is selected, the next step is to find the best 
split of     by evaluating all possible splits. The two-sample linear statistic, which 
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measures the discrepancy between the two disjoint subsets created by a split of   
 , 
A and   
 /A, is calculated as follows:  
   
 (  , w)=vec(∑   
 
    (      )               
 )  (10) 
where    (.) is the indicator function. The best split is the one that maximizes the test 
statistic over all possible subsets A. 
 
4.2  Modeling Results of SPINEZ_FIRST 
The first response variable of the study is SPINEZ_FIRST, the patient’s 
DXA Z-score at his/her first DXA assessment visit. We used both the RPART and 
PARTY packages to build models of SPINEZ_FIRST, using 10-fold cross-
validation in RPART models and the Bonferroni-adjusted p-value of 0.95 in 
PARTY models. The minimum number of records in each leaf node is set to 20 
(about 2% of all the records in the data set). The 12 variables used to build the 
models of SPINEZ_FIRST are summarized in Table 7. 
Table 7. Variables Used to Build the Models of SPINEZ_FIRST 
Variable Meaning Type and Value 
AGEINF 
patients’ age at first infusion(in 
years) 
numeric 
BISPHOS 
whether the patient had treatment 
with 
bisphosphonates 
binary (yes/no) 
SEX gender binary (male/female) 
ETHGRP patient's ethnicity group 
categorical (African- 
American; American- 
Indian; Arab; Asian; 
Caucasian; Hispanic; 
Jewish- Ashkenazi; 
Jewish- 
Both Ashkenazi and 
Sephardic; Jewish-
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Neither 
Ashkenazi nor 
Sephardic; 
Jewish- Sephardic; 
Multi- 
Ethnic) 
REGION patient's geographic region 
categorical (Americas; 
Asia, Pacific, S. Africa; 
Europe; Middle East; 
USA) 
BIWEEK_FIRST_VI
SIT 
the number of bi-weeks between first 
infusion and first DXA assessment 
visit 
numeric 
DOSE3Y 
average dose of imiglucerase  (in 
U/kg/2wks) 
numeric 
BMIB 
a patient's body mass index at the 
first infusion 
numeric 
THROM_HEPATO 
combine THROM and HEPATO to 
see how many of 
them were categorized as "severe" 
numeric (0, 1, 2) 
SPLSTAT_SPLENO 
combine SPLSTAT and SPLENO to 
see whether 
SPLSTAT is “ever splenectomized” 
or SPELNO is“severe” 
binary 
(severe/not severe) 
BONE_PROBLEMS 
combine INFARC, EFD, AVN, 
MARR, FRACT, LYTIC 
and OSTEO to see how many of 
these variables 
were reported “yes” for a patient 
numeric (0,1,2,3,4,5,6) 
BONE_PAIN 
combine BPAINPM, BPAINSEV, 
and BCRISLS to see whether for a 
patient, his/her BPAINPM was 
recorded as“yes” and BPAINSEV as 
"severe" or “extreme”, or his/her 
BCRISLS was recorded as “yes”. if 
so, BONE_PAIN was assigned “yes”,  
otherwise, it is “no” 
binary(yes/no) 
 
According to the modeling results of SPINEZ_FIRST, the most predictive 
variables are REGION, BISPHOS, SEX, and BIWEEK_FIRST_VISIT although 
other variables included in different models vary.  All the models of 
SPINEZ_FIRST derived using the PARTY package are the same, as they do not 
include any variable with missing values. The models of SPINEZ_FIRST derived 
from the RPART package, on the other hand, are similar for the complete datasets 
with the same imputed ETHGRP values but different for those with different 
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imputed BMIB values. We present 3 models derived using the RPART package 
from 3 complete datasets, as well as the model derived from the original dataset 
using the RPART package. The other 9 tree models derived in the study are 
reported in the appendix. 
 
4.2.1 Models of SPINEZ_FIRST  by Using PARTY package  
Figure 14 illustrates the regression tree model of SPINEZ_FIRST developed 
using the PARTY package, in which the 3 numbers, from top to bottom, underneath 
each leaf node show the number of records, the mean, and standard deviation of 
SPINEZ_FIRST of the node, respectively. The model suggests that for the patients 
who had bisphosphonates, female patients had significantly higher values of 
SPINEZ_FIRST than male patients (t-test, p=0.0002). Among the patients who 
didn’t have bisphosphonates, those in Asia, Pacific, S.Africa, Europe and the USA 
had significantly higher values of SPINEZ_FRIST than those in other regions (t-
test, p<0.0001). Additionally, patients who had large values of 
BIWEEK_FIRST_VISIT (the number of bi-weeks between the patients’ first 
infusion visits and their first DXA assessment visits) had significantly higher values 
of SPINEZ_FIRST than those with smaller values of BIWEEK_FIRST_VISIT (t-
test, p=0.0006). 
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Figure 14. Model of SPINEZ_FIRST Derived Using the PARTY Package from All the 
Individual Complete Datasets and the Original Dataset 
(The 3 numbers, from top to bottom, underneath each leaf node, show the number of 
records, the mean, and standard deviation of SPINEZ_FIRST of the node, respectively.) 
 
4.2.2 Models of SPINEZ_FIRST Using the RPART Package 
Figure 15 illustrates the first regression tree model of SPINEZ_FIRST 
developed using the RPART package. Compared to Figure 14, Figure 15 includes 
Female Male 
>39 <=39 
Americas, 
Middle East 
Asia, Pacific, 
S.Africa, 
Europe, USA
 
No Yes 
REGION SEX 
BIWEEK_FIRST_VISIT 
 N=552                  N=89                     N=93                       N=96                      N=59 
-0.669                    -1.60                     -0.75                      -1.103                    -1.754 
(1.211)                 (1.061)                  (1.204)                    (1.225)                 (0.852) 
BISPHOS 
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more variables in the tree model. First, patients were divided into two groups based 
on REGION. Among the patients in Europe, those who had higher values of 
BIWEEK_FIRST_VISIT have significantly higher SPINEZ_FIRST values than 
others. Among the patients who resided in the other regions and had 
bisphosphonates, female patients had significantly higher values of 
SPINEZ_FIRST than male patients. For the patients who did not have 
bisphosphonates and whose values of BIWEEK_FIRST_VISIT were below 159.5, 
their values of SPINEZ_FIRST values were affected by ETHGRP, AGEINF and 
BMIB. More specifically, African American, Asian, both Ashkenazi and Sephardic 
Jewish, neither Ashkenazi nor Sephardic Jewish, and multi-ethnic patients had 
significantly smaller SPINEZ_FIRST values than those in other ethnicity groups (t-
test, p=0.0003). Additionally, among the American Indian, Arab, Hispanic, 
Caucasian, Jewish-Ashkenazi, and Jewish-Sephardic patients, those younger than 
11 years old had significantly higher values of SPINEZ_FIRST than older patients 
(t-test, p=0.0006), and those whose body mass index at their first infusion were 
higher than 22.82 had significantly higher value of SPINEZ_FIRST than others (t-
test, p=0.0004). 
Figure 16 illustrates the second regression tree model of SPINEZ_FIRST 
developed using the RPART package from a complete dataset with the same 
imputed values of ETHGRP but with different imputed BMIB values, as those in 
Figure 15. The major difference between Figures 15 and 16 is that BMIB has more 
detailed partitions given AGEINF. Like Figure 15, Figure 16 also suggests that the 
patients with higher value of BMIB had larger value of SPINEZ_FIRST. 
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Figure 17 illustrates the third regression tree model of SPINEZ_FIRST 
developed using the RPART package from a complete dataset with different 
imputed ETHGRP values and different imputed BMIB values as those in Figure 15. 
There are two major differences between Figures 15 and 17. First, for the patients 
whose BIWEEK_FIRST_VISIT values were no greater than 101.5, their 
SPINEZ_FIRST values were affected by their values of BMIB, particularly those 
with larger values of BMIB had significantly higher values of SPINEZ_FIRST. 
Second, the SPINEZ_FIRST values of female patients were affected by REGION. 
More specifically, the patients in Europe had significantly lower SPINEZ_FIRST 
values than the patients in other regions (t-test, p=0.0003).  
Figure 18 illustrates the tree model of SPINEZ_FIRST developed using the 
RPART package from the original dataset. It is very similar to Figure 17, except for 
one main difference: neither Ashkenazi nor Sephardic Jewish and Multi-Ethnic 
patients are grouped together with American Indian, Arab, Caucasian, Hispanic, 
Sephardic Jewish, and Ashkenazi Jewish patients in Figure 18, rather than with 
African American, Asian, and both Ashkenazi and Sephardic Jewish patients, as 
shown in Figure 17. 
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Figure 15. Model 1 of SPINEZ_FIRST Derived Using the RPART Package from a 
Complete Dataset 
 
<=101.5 >101.5 
N=81         N=32         N=49         N=78          N=44       N=87       N=200    N=174      N=144    
-1.717      -0.898       -1.683       -0.964         -1.343     -0.359     -1.055    -0.617       -0.387  
(1.058)     (1.260)      (0.831)     (1.218)       (1.103)   (1.185)   (1.212)    (1.094)    (1.223) 
<=22.82 >22.82 
African American, 
Asian, Jewish (both 
Ashkenazi and 
Sephardic), Jewish 
(neither Ashkenazi 
nor Sephardic), 
multi- Ethnic                                                                
<=11 >11 
<=159.5 >159.5 
Mal
e 
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Yes No 
Americas, Asia, Pacific, S. Africa, Europe, USA Middle East 
American Indian, Arab, 
Hispanic, Caucasian, 
Jewish-Ashkenazi, 
Jewish-Sephardic 
BIWEEK_FIRST_VISIT BISPHOS 
SEX 
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AGEINF 
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BIWEEK_FIRST_VISIT 
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Figure 16. Model 2 of SPINEZ_FIRST Derived Using the RPART Package from a 
Complete Dataset 
(The complete dataset has the same imputed ETHGRP values as those used in Figure 15 
but with different imputed BMIB values.) 
Americas, Asia, Pacific, S. Africa, Europe, 
USA 
<=18.0 <=19.2 
<=101.5 >101.5 
>19.2 >18.0
 
<=11 
African American, 
Asian, Jewish 
(both Ashkenazi 
and Sephardic), 
Jewish (neither 
Ashkenazi nor 
Sephardic), multi- 
Ethnic                                                                
  >11 
<=159.5 >159.5 
Male Female 
Yes No 
Middle East 
American Indian, 
Arab, Hispanic, 
Caucasian, Jewish-
Ashkenazi, Jewish-
Sephardic 
BISPHOS 
SEX 
ETHGRP 
AGEINF 
BMIB BMIB 
BIWEEK_FIRST_VISIT 
BIWEEK_FIRST_VISIT 
 N=81       N=32     N=49       N=78      N=44        N=62     N=25      N=89    N=285   N=144       
-1.717      -0.898   -1.683    -0.964    -1.343      -0.615    -0.276    -1.314   -0.706    -0.387 
(1.058)    (1.260)   (0.831)   (1.218)  (1.103)    (1.136)   (1.075)   (1.151)  (1.150) (1.223) 
REGION             
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Figure 17. Model 3 of SPINEZ_FIRST Derived Using the RPART Package from a 
Complete Dataset 
(The complete dataset has different imputed ETHGRP and BMIB values from those used 
in Figures 15 and 16.) 
N=30      N=51     N=32      N=49     N=14     N=64      N=44     N=87    N=96    N=287     N=144     
-2.291   -1.380   -0.898    -1.683   -1.800    -0.781    -1.343   -0.359  -1.245    -0.715    -0.387 
(0.806)   (1.050)  (1.260)  (0.831)  (0.776)  (1.225)  (1.103)  (1.185)  (1.204) (1.139)  (1.223) 
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Figure 18. Model 4 of SPINEZ_FIRST Derived Using the RPART Package from the 
Original Dataset 
 
N=20       N=39         N=32         N=49        N=78        N=23       N=78    N=57       N=179    N=144         
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Ethnic                                                             
African 
American, 
Asian, Jewish 
(both Ashkenazi 
and Sephardic)                            
REGION             
BISPHOS 
SEX 
ETHGRP 
AGEINF 
BMIB 
BMIB 
BIWEEK_FIRST_VISIT 
BIWEEK_FIRST_VISIT 
 
53 
 
4.3  Modeling Results of FIRST_RATE_SPINEZ 
Only the patients who had at least two DXA assessment visits are used to 
build models of FIRST_RATE_SPINEZ. In addition, 3 outliers whose values of 
FIRST_RATE_SPINEZ were greater than 0.15 or less than -0.15 are removed. As a 
result, only data from 471 patients with 1066 records are used to build models of 
FIRST_RATE_SPINEZ.  
The variables used to build the models of FIRST_RATE_SPINEZ are 
summarized in Table 8. In addition to the variables used to build the models of 
SPINEZ_FIRST, as listed in Table 7, the response variable discussed in section 4.2 
is also included as a predictor in building the models of FIRST_RATE_SPINEZ. 
Besides, FIRST_BIWEEK_UP, the number of bi-weeks between a patient’s first 
DXA assessment visit and each of his/her follow-up DXA assessment visits, is 
another new variable in the models of FIRST_RATE_SPINEZ. 
         Table 8. The Variables Used in Building Models of FIRST_RATE_SPINEZ 
Variable Meaning Type and Value 
AGEINF 
patients’ age at first infusion(in 
years) 
numeric 
BISPHOS 
whether the patient had treatment 
with 
bisphosphonates 
binary (yes/no) 
SEX gender binary (male/female) 
ETHGRP patient's ethnicity group 
categorical (African- 
American; American- 
Indian; Arab; Asian; 
Caucasian; Hispanic; 
Jewish- Ashkenazi; 
Jewish- 
Both Ashkenazi and 
Sephardic; Jewish-Neither 
Ashkenazi nor Sephardic; 
Jewish- Sephardic; Multi- 
Ethnic) 
REGION patient's geographic region categorical (Americas; 
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Asia, Pacific, S. Africa; 
Europe; Middle East; 
USA) 
BIWEEK_ 
FOLLOW_VISIT 
the number of bi-weeks between each 
patient’s first DXA Z-Score visit and 
each of the following-up DXA Z-
Score visits 
numeric 
DOSE3Y 
average dose of imiglucerase  (in 
U/kg/2wks) 
numeric 
BMIB 
a patient's body mass index at the 
first infusion 
numeric 
THROM_HEPATO 
combine THROM and HEPATO to 
see how many of 
them were categorized as "severe" 
numeric (0, 1, 2) 
SPLSTAT_SPLENO 
combine SPLSTAT and SPLENO to 
see whether 
SPLSTAT is “ever splenectomized” 
or SPELNO is“severe” 
binary 
(severe/not severe) 
BONE_PROBLEMS 
combine INFARC, EFD, AVN, 
MARR, FRACT, LYTIC, and 
OSTEO to see how many of these 
variables were reported “yes” for a 
patient 
numeric (0,1,2,3,4,5,6) 
BONE_PAIN 
combine BPAINPM, BPAINSEV, 
and BCRISLS to see whether for a 
patient, his/her BPAINPM was 
recorded as“yes” and BPAINSEV as 
"severe" or “extreme”, or his/her 
BCRISLS was recorded as “yes”. if 
so, BONE_PAIN was assigned “yes”,  
otherwise, it is “no” 
binary(yes/no) 
SPINEZ_FIRST 
the DXA Z-Score at each patient’s 
first DXA assessment visit. 
numeric 
 
4.3.1 Models of FIRST_RATE_SPINEZ Using PARTY Package 
Figure 19 illustrates the model of FIRST_RATE_SPINEZ developed using 
the PARTY package from the 12 complete datasets and from the original dataset, 
which suggests that the patients with higher SPINEZ_FIRST values had 
significantly lower FIRST_RATE_SPINEZ values than those with lower 
SPINEZ_FIRST values. In particular, most patient whose SPINEZ_FIRST values 
were greater than 0.36 had negative FIRST_RATE_SPINEZ values, and the 
patients in Europe had significantly lower FIRST_RATE_SPINEZ values than 
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those in other regions (t-test, p<0.0001). For the patients in Americas, Asia, Middle 
East, USA, Pacific, and S. Africa, whose SPINEZ_FIRST values ranged from -2.7 
to 0.36, their values of FIRST_RATE_SPINEZ were related to SEX, AGEINF, 
BIWEEK_ FIRST_VISIT, BISPHOS, and ETHGRP. In particular, Asian, 
Caucasian, Ashkenazi Jewish, both Ashkenazi and Sephardic Jewish, neither 
Ashkenazi nor Sephardic Jewish, and Multi-Ethnic patients had significantly 
smaller FIRST_RATE_SPINEZ values than the patients in other ethnic groups (t-
test, p<0.0001). Among these patients, those who had bisphosphonates had 
significantly lower FIRST_RATE_SPINEZ values than those without (t-test, 
p<0.0001). Male patients had significantly lower values of FIRST_RATE_SPINEZ 
than female patients (t-test, p<0.0001). Among these female patients, those with 
lower values of BIWEEK_ FOLLOW_VISIT tended to have higher values of 
FIRST_RATE_SPINEZ. 
 
 
 
 
 
 
 
 
 
 
 
56 
 
 
 
         
 
                          
                                                                                                                                     
                                                                                                                                                                  
                                                                                                                 
                                                                                                                                        
                                                                  
                                                                                
                                                                                 
 
                                           
                      
                                                                                      
                                    
                                                                                                                                                                             
                             
            
 
Figure 19. Model of FIRST_RATE_SPINEZ Derived Using the PARTY Package from the 
12 Complete Datasets and from the Original Dataset. 
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4.3.2 Models of FIRST_RATE_SPINEZ Using RPART Package  
Figure 20 illustrates the model of FIRST_RATE_SPINEZ developed using 
the RPART package from the 12 complete datasets. From the figure, we can see 
that SPINEZ_FIRST and REGION are two most predictive variables of 
FIRST_RATE_SPINEZ. Most patients whose SPINEZ_FIRST values were larger 
than 0.36 had negative FIRST_RATE_SPINEZ values. For the patients whose 
SPINEZ_FIRST values ranged from -2.7 to 0.36, their values of 
FIRST_RATE_SPINEZ were related to ETHGRP and REGION. More specifically, 
African American, American Indian, Arab, and Hispanic patients had significantly 
higher FIRST_RATE_SPINEZ values than the other patients (t-test, p<0.0001). 
Among the Asian, Caucasian, Ashkenazi Jewish, both Ashkenazi and Sephardic 
Jewish, neither Ashkenazi nor Sephardic Jewish, and multi-Ethnic patients, those in 
Europe had significantly lower values of FIRST_RATE_SPINEZ than those in 
other regions (t-test, p<0.0001). 
Figure 21 illustrates the model of FIRST_RATE_SPINEZ developed using 
the RPART package from the original dataset. It is very similar to Figure 20, except 
for one difference:  compared to Figure 20, Figure 21 had an additional predictor 
BMIB in the model. Among the patients in the Americas, Asia, Pacific, S. Africa, 
Middle East and the USA, those whose BMIB values were greater than 15.5 had 
significantly higher value of FIRST_RATE_SPINEZ than those in other regions (t-
test, p<0.0001). 
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Figure 20. Model of FIRST_RATE_SPINEZ Derived Using the RPART Package 
from All the Complete Datasets 
 
 
>0.37 >0.37 
Europe 
<=-2.66 >-2.66 
Europe Americas, Asia, Pacific, S.Africa, 
Middle East, USA      
Americas, Asia, 
Pacific, S.Africa, 
Middle East, USA      
African American, 
American Indian, 
Arab, Hispanic
Asian, Caucasian, 
Jewish-Ashkenazi, 
Jewish-Sephardic, 
Jewish (both 
Ashkenazi and 
Sephardic), Jewish 
(neither Ashkenazi 
nor Sephardic), 
Multi-Ethnic                                                                                                                          
                                                                                                                                                                     
SPINEZ_FIRST 
REGION 
ETHGRP 
REGION 
SPINEZ_FIRST 
 N=84                  N=204               N=560                N=72                  N=56               N=90             
0.014                   -0.002               0.003                  0.012                 -0.020           -0.001 
(0.019)                (0.016)              (0.013)              (0.022)               (0.0267)       (0.014) 
                 
 
59 
 
 
 
                                               
 
  
                                                                                      
                                                                                             
                                                                                                                     
                                                                                                                                                                                
                                                                                         
                                                                  
                                                                                                                                                                                           
                                                                  
                                                                  
  
                                                                        
                                
                  
                 
 
Figure 21. Model of FIRST_RATE _ SPINEZ Derived Using the RPART Package from        
the Original Dataset 
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4.4  Modeling Results of RATE_SPINEZ 
Like the dataset used to build the models of FIRST_RATE_SPINEZ, the 
dataset used to build the models of RATE_SPINEZ also only contains the patients 
who had multiple DXA assessment visits. Besides, 2 outliers whose 
RATE_SPINEZ values are larger than 0.2 or smaller than -0.2 are removed. As a 
result, data from 471 patients with 1067 records are used to derive models of 
RATE_SPINEZ. 
Table 9 summarizes the variables used to build the models of 
RATE_SPINEZ. Compared to Table 8, Table 9 does not include 
FIRST_BIWEEK_UP or SPINEZ_FIRST, but it contains PREVIOUS_ SPINEZ, 
which represents the patient’s DXA Z-score at his/her immediately previous DXA 
assessment visit, and BIWEEK_COVISIT, which refers to the number of bi-weeks 
between the patient’s two consecutive DXA assessment visits. 
Table 9. Variables Used to Build Models of RATE_SPINEZ 
Variable Meaning Type and Value 
AGEINF 
patients’ age at first infusion (in 
years) 
numeric 
BISPHOS 
whether the patient had treatment 
with 
bisphosphonates 
binary (yes/no) 
SEX gender binary (male/female) 
ETHGRP patient's ethnicity group 
categorical (African- 
American; American- 
Indian; Arab; Asian; 
Caucasian; Hispanic; 
Jewish- Ashkenazi; 
Jewish- 
Both Ashkenazi and 
Sephardic; Jewish-Neither 
Ashkenazi nor Sephardic; 
Jewish- Sephardic; Multi- 
Ethnic) 
REGION patient's geographic region categorical (Americas; 
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Asia, Pacific, S. Africa; 
Europe; Middle East; 
USA) 
BIWEEK_COVISIT 
the number of bi-weeks between 
two successive  DXA Z-Score visits 
numeric 
DOSE3Y 
average dose of imiglucerase  (in 
U/kg/2wks) 
numeric 
BMIB 
a patient's body mass index at the 
first infusion 
numeric 
THROM_HEPATO 
combine THROM and HEPATO to 
see how many of 
them were categorized as "severe" 
numeric (0, 1, 2) 
SPLSTAT_SPLENO 
combine SPLSTAT and SPLENO 
to see whether 
SPLSTAT is “ever splenectomized” 
or SPELNO is“severe” 
binary 
(severe/not severe) 
BONE_PROBLEMS 
combine INFARC, EFD, AVN, 
MARR, FRACT, LYTIC 
and OSTEO to see how many of 
these variables 
were reported “yes” for a patient 
numeric (0,1,2,3,4,5,6) 
BONE_PAIN 
combine BPAINPM, BPAINSEV, 
and BCRISLS to see whether for a 
patient, his/her BPAINPM was 
recorded as“yes” and BPAINSEV 
as "severe" or “extreme”, or his/her 
BCRISLS was recorded as “yes”. if 
so, BONE_PAIN was assigned 
“yes”,  otherwise, it is “no” 
binary(yes/no) 
PREVIOUS_SPINEZ 
the DXA Z-Score in each patient’s 
immediately previous DXA 
assessment visit 
numeric 
  
The models of RATE_SPINEZ developed using the PARTY and RPART 
packages are much simpler than the models of the other two response variables. All 
the models of RATE_SPINEZ suggest that PREVIOUS_SPINEZ is the most 
predictive variable of RATE_SPINEZ. 
4.4.1 Models of RATE_SPINEZ Developed Using the PARTY Package 
Figure 22 illustrates the model of RATE_SPINEZ developed using the 
PARTY package from all of the 12 complete datasets and from the original dataset, 
which suggests that PREVIOUS_SPINEZ is the only important predictive variable 
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of RATE_SPINEZ. Particularly, the lower the PREVIOUS_SPINEZ, the higher the 
RATE_SPINEZ. 
 
 
  
                                                                     
           
  
                                  
 
                        
                                                                    
 
Figure 22. Model of RATE_SPINEZ Derived Using the PARTY Package from All the 
Individual Complete Datasets and from the Original Dataset 
 
4.4.2 Models of RATE_SPINEZ Developed Using the RPART Package 
Figure 23 illustrates the model of RATE_SPINEZ developed using the 
RPART package from all the complete datasets. It suggests that most patients 
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whose BIWEEK_COVISIT values were less than 14.5 had negative values of 
RATE_SPINEZ. Otherwise, for the patients whose BIWEEK_COVISIT values 
were greater than 14.5, and PREVIOUS_SPINEZ values were less than -2.595, 
their values of RATE_SPINEZ are affected by ETHGRP. More specifically, 
African American, Ashkenazi Jewish, and Multi-Ethnic patients had significantly 
lower values of RATE_SPINEZ than the other patients (t-test, p<0.0001). For the 
patients in the other ethnicity groups, whose BIWEEK_COVISIT values were more 
than 14.5, their RATE_SPINEZ values were only related to PREVIOUS_SPINEZ: 
the lower the PREVIOUS_SPINEZ, the higher the RATE_SPINEZ.  
Figure 24 illustrates the model developed from the original dataset using the 
RPART package. It is almost identical to Figure 23, except with one difference: 
ETHGRP in Figure 23 is replaced by BMIB in Figure 24. In particular, the patients 
with BMIB values less than 22.5 had significantly lower values of RATE_SPINEZ 
than those with higher BMIB values. 
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Figure 23. Model of RATE_SPINEZ Derived Using the RAPRT Package from All the 
Complete Datasets 
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Figure 24. Model of RATE_SPINEZ Derived Using the RAPRT Package from the 
Original Dataset 
 
4.5  Summary of Key Findings 
We summarize the key findings from the derived models of 
SPINEZ_FIRST, FIRST_RATE_SPINEZ and RATE_SPINEZ. 
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<=-1.495  >-1.495 
<=14.5 >14.5 
>22.5 <=22.5 
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BIWEEK_COVISIT 
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-0.027          0.018     0.007              0.018          0.0004       
(0.046)         (0.032)             (0.021)          (0.034)        (0.020)
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4.5.1 Findings of SPINEZ_FIRST  
All the models of SPINEZ show that the most predictive variables of 
SPINEZ_FIRST are REGION (the patient’s geographic region), BISPHOS 
(whether the patient had bisphosphonates), SEX (patients’ gender) and 
BIWEEK_UP_FIRST (the number of bi-weeks between the patient’s first infusion 
and his/her first DXA assessment visit). More details are as follows: 
 Patients who had larger values of BIWEEK_UP_FIRST had significantly 
larger values of SPINEZ_FIRST than those with smaller values of 
BIWEEK_UP_FIRST. 
 Among the patients in Middle East, their values of SPINEZ_FIRST were 
affected by BIWEEK_UP_FIRST. Those with larger values of 
BIWEEK_UP_FIRST had higher values of SPINEZ_FIRST. 
 Among the patients who had bisphosphonates, their values of 
SPINEZ_FIRST were affected by SEX. Particularly, female patients had 
significantly higher values of SPINEZ_FIRST than male patients. 
 
4.5.2 Models of FIRST_RATE_SPINEZ 
All the models of FIRST_RATE_SPINEZ suggest that the most predictive 
variables of FIRST_RATE_SPINEZ are REGION, SPINEZ_FIRST, and ETHGRP. 
More details are listed as follows: 
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 Patients with smaller SPINEZ_FIRST values had significantly higher values 
of FIRST_RATE_SPINEZ than the patients with larger SPINEZ_FIRST 
values.  
 Patients with SPINEZ_FIRST less than -2.66 had the largest 
FIRST_RATE_SPINEZ, while most patients with SPINEZ_FIRST greater 
than 0.36 had negative FIRST_RATE_SPINEZ.                        
 For the patients with SPINEZ_FIRST ranging between -2.66 and 0.36, their 
values of FIRST_RATE_SPINEZ were affected by REGION and ETHGRP. 
Those in Europe had significantly lower values of FIRST_RATE_SPINEZ 
than those in other regions. In addition, African American, American Indian, 
Arab, and Hispanic patients had significantly larger values of 
FIRST_RATE_SPINEZ than the other patients. 
 
4.5.3 Models of RATE_SPINEZ 
All the models of RATE_SPINEZ suggest that the most predictive variables 
of RATE_SPINEZ is PREVIOUS_SPINEZ. In particular, patients with smaller 
PREVIOUS_SPINEZ had greater RATE_SPINEZ than those with larger 
PREVIOUS_SPINEZ. 
 
V. Discussion and Conclusions 
In this research, we have applied two regression tree methods – RPART and 
PARTY packages in R – to build models for three response variables: 
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SPINEZ_FIRST, FIRST_RATE_SPINEZ, and RATE_SPINEZ. For each response 
variable, models have been derived from 12 complete datasets that contain 
variations of imputed values for missing covariates, as well as from the original 
data set with missing values. The regression trees may have different structures by 
using different methodologies, because of the variations in the imputed values of 
ETHGRP and BMIB, and different approaches to selecting splits and stopping rules 
in RPART and PARTY packages, the derived models were consistent in terms of 
the most predictive covariates of the response variable. In particular, the most 
predictive covariates of SPINEZ_FIRST are REGION, BISPHOS, SEX and 
BIWEEK_UP_FIRST, the most predictive covariates of FIRST_RATE_SPINEZ 
are REGION, SPINEZ_FIRST, and ETHGRP, and the most predictive covariate of 
RATE_SPINEZ is PREVIOUS_SPINEZ.  
The modeling results of SPINEZ_FIRST suggest that the longer the 
duration between a patient’s first infusion of imiglucerase and his/her first DXA 
assessment visit is, the larger the patient’s bone-mineral density tends to be. It can 
be assumed that most patients had a relatively low bone density at the beginning of 
the treatment, and it takes some time before the patients can benefit from the ERT 
treatment. Therefore, if there was a longer period between the start of the treatment 
and the first DXA assessment, the beneficial effect of the treatment could manifest 
itself for a longer period, and the bone-mineral density would be higher as a result. 
For those who had the treatment with bisphosphonates, female patients 
tended to have higher initial bone-mineral density than male patients. 
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Regarding the rate of change in a patient’s DXA Z-score between the 
patient’s first infusion and each of his/her following DXA assessment visits, the 
models suggest that the patients with a lower value of bone-mineral density at the 
beginning of the treatment caught up to the normal level of bone-density more 
quickly. It is also interesting to notice that among the patients whose initial DXA Z-
score values were from -2.66 to 0.36, those from Europe profited less from the 
treatment than the patients from other regions. 
When the rate of bone-mineral density change between successive 
measurements is evaluated, the most predictive variable is the previous bone-
mineral density value. In particular, patients with lower previous bone-mineral 
density had more improvement from the treatment. This is again consistent with the 
theory that patients with lower bone-mineral density have more of a need to catch 
up.  
Another interesting finding is that the treatment dosage only appears twice 
in the models of FIRST_SPINEZ, and it only affects Arab, Hispanic, Caucasian, 
Jewish-Ashkenazi, Jewish-Sephardic, and American Indian patients. Among these 
patients, a higher dosage led to faster improvement of bone-mineral density in 
general. 
None of the new variables constructed from patient’s hematological, 
visceral, and bone manifestations show up as important predictive covariates of the 
three response variables studied in the research. 
 
 
 
70 
 
List of References: 
Allison, D.P. (2001). Missing data (Quantitative Applications in the Social 
Sciences). Thousand oaks, California: Sage Publications, Inc.  
Andersson, H., Kaplan, P., Kacena, K., & Yee, J. (2008). Eight-Year Clinical 
Outcomes of Long-Term Enzyme Replacement Therapy for 884 Children 
with Gaucher Disease Type 1. Journal of Pediatrics, 122, 2007-2144.  
Bembi, B., Ciana, G., Mengel, E., Terk, M.R., Martini, C., & Wenstrup, R. J. 
(2002). Bone complications in children with Gaucher disease.  The British 
Journal of Radiology, 75, A37–A43. 
Bolker, M., Brooks, E., Clark, J., Geange, W., Poulsen, R., Stevens, H., & White, S. 
(2008). Generalized Linear Mixed Models: A Practical Guide for Ecology 
and Evolution. Journal of Trends in Ecology and Evolution, 24, 127-135.  
Breiman, L., Friedman, J., Olshen, R. & Stone, C. (1984).  Classification and 
Regression Trees. Wadsworth, CA: Pacific Grove.  
Charrow, J., Dulissec, B., Grabowski, G.A., & Weinreb, N.J. (2007). The effect of 
enzyme replacement therapy on bone crisis and bone pain in patients with 
type 1 Gaucher disease. Journal of Clin Genet, 71, 205–211.  
Chen, G., & Astebro, T. (2003). How to deal with missing categorical data: Test of 
a simple Bayesian method. Journal of Organizational Research Methods, 
6(3), 309-327. 
Data mining tools. (n.d.).  An Introduction to Data Mining. Retrieved September 3, 
2011, from 
http://dataminingtools.net/wiki/introduction_to_data_mining.php 
 
 
71 
 
Dobra, A. (2002). Classification and Regression Tree Construction. Retrieved 
September 18, 2011, from Cornell University, Department of Computer 
Science. 
Elstein, D., Abrahamov, A., Halpern, I. H., Meyer, A., & Zimran, A. (1998). Low-
dose low-frequency imiglucerase as a starting regimen of enzyme 
replacement therapy for patients with type I Gaucher disease. Journal of Q J 
Med, 91, 483-488. 
Fayyad, M.U., Piatetsky-Shapiro, G., & Smyth, P. (1996). From data mining to 
knowledge discovery: an Overview. Advances in Knowledge Discovery and 
Data Mining (pp. 1-36). Menlo Park, CA, USA: American Association for 
Artificial Intelligence. 
Journal of American Society of Hemotology. (March 9, 2006) Superior effects of 
high-dose enzyme replacement therapy in type 1 Gaucher disease on bone 
marrow involvement and chitotriosidase levels: a 2-center retrospective 
analysis. Retrieved August 11, 2011 from 
bloodjournal.hematologylibrary.org. 
Han, J., Kamber, M., & Pei, J. (2011). Classification: Basic Concepts. Data Miming: 
Concepts and Techniques (pp. 344). CA: AAAI Press. 
Hothorn, T., Hornik, K., & Zeileis, A. (2006). Unbiased Recursive Partitioning: A 
Conditional Inference Framework, Journal of Computational and Graphical 
Statistics, 15, 651-674. 
Hui, S.L., Gao, S.J., Zhou, X.H., Johnston, C.C., Lu, Y., Gluer, C.C., et al. 
(1997).Universal Standardization of Bone Density Measurements: A 
Method with Optimal Properties for Calibration Among Several Instruments. 
Journal of Bone and Mineral Research, 12, 1463-1470. 
Kalton, G. & Kasprzyk, D. (1986).  The Treatment of Missing Survey Data.  
Journal of Survey Methodology, 12, 1-16. 
 
72 
 
Kass, G.V. (1980). An exploratory technique for investigating large quantities of 
categorical data. Journal of Applied Statistics, 29, 119-127. 
Little, A. & Rubin, B. D. (1987).  Statistical Analysis with Missing Data. (2
nd
 e.d.). 
Hoboken, New Jersey: John & Wiley. 
Liu, Y. (2006). Interactive visual data mining modeling to enhance understanding 
and effectiveness of the process. Retrieved September 18, 2011, from 
Purdue University. 
McLachlan, J.G., Do, K.A., & Ambroise, C. (2004). Analyzing Microarray Gene 
Expression Data (Wiley Series in Probability and Statistics). Hoboken, New 
Jersey: John & Wiley. 
Mistry, P.K., Weinreb, N.J., Kaplan, P., Alexander, J.C., Gwosdow, A.R., & 
Hangartner, T. (2011), Osteopenia in Gaucher disease develops early in life: 
Response to imiglucerase enzyme therapy in children, adolescents and 
adults, Journal of Blood Cells Mol Disease, 46(1), 66-72. 
Murthy, S. K. (1998). Automatic construction of decision trees from data: a multi-
disciplinary survey.  Journal of Data Mining and Knowledge Discovery, 
2(4), 345-389. 
Poll, L.M., Maas, M., Terk, M.R., Roca-Espiau, M., Bembi, B., Ciana, G., & 
Weinreb, N. J. (2002). Response of Gaucher bone disease to enzyme 
replacement therapy. The British Journal of Radiology, 75, A25–A36. 
Quinlan, J.R. (1986). Induction of Decision Trees. Journal of Machine Learning, 1, 
81-106.  
Quinlan, J.R. (1993).  C 4.5 -- Programs for Machine Learning. CA: Morgan 
Kaufmann.  
Rosenthal, D.I., Doppelt, S.H., Mankin, H.J., Dambrosia, J.M., Xavier, R.J., 
McKusick, K.A., et al. (1995). Enzyme replacement therapy for Gaucher 
 
73 
 
disease: skeletal responses to macrophage-targeted glucocerebrosidase. 
Journal of Pediatrics, 96, 629–637. 
Roth, P. (1994). Missing data: A conceptual review for applied psychologists. 
Journal of Personnel Psychology, 47, 537-560. 
Roth, P. L., & Switzer, F. S. (1995). A Monte Carlo Analysis of Missing Data 
Techniques in a HRM Setting. Journal of Management, 21(5), 1003-1023. 
Sims, K.B., Pastores, G.M., Weinreb, N.J., Barranger, J., Rosenbloom, B.E., 
Packman, S., et al. (2008). Improvement of bone disease by imiglucerase 
(Cerezyme) therapy in patients with skeletal manifestations of type 1 
Gaucher disease: results of a 48-month longitudinal cohort study. Journal of 
Clin Genet, 73, 430–440. 
The Data Mining Process. (n.d.) Retrieved September 3, 2011, from 
http://www.dataminingexpertsolutions.com/dm-process/ 
Therneau, M., Atkinson, M., Foundation, M. (1997). An Introduction to Recursive 
Partitioning Using the RPART Routines. Retrieved May 18, 2011, from 
http://www.mayo.edu/hsr/techrpt/61.pdf 
Timofeev, R. (2004). Classification and Regression Trees (CART) Theory and 
Applications. Retrieved December 6, 2011, from Center of Applied 
Statistics and Economics Humboldt University, Berlin. 
Tóth, J., Szücs F.Z., Benkö, K., Maródi, L. (2003). Enzyme replacement therapy in 
Gaucher disease: monitoring visceral and bone changes with MRI. Journal 
of Orv Hetil, 144, 749-755. 
Wayman. J. (2003). Multiple Imputation For Missing Data:  What Is It And How 
Can I Use It? Retrieved May 11, 2011, from Center for Social Organization 
of Schools, John Hopkins University. 
 
74 
 
Weinreb, N. J., Charrow, J., Andersson, H. C., Kaplan, P., Kolodny, E. H., Mistry, 
P., et al. (2002). Effectiveness of enzyme replacement therapy in 1028 
patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report 
from the Gaucher Registry, Journal of Excerpta Medica, 113, 112-119.  
Weinreb, N., Barranger, J., Packman, S., Prakash-Cheng, A., Rosenbloom, B., Sims, 
K., et al. (2007). Imiglucerase (Cerezyme) improves quality of life in 
patients with skeletal manifestations of Gaucher disease. Journal of Clinical 
Genetics, 71, 576-588. 
Wenstrup, R.J., Kacena, K.A., Kaplan, P., Pastores, G.M., Cheng, A.P., Zimran, A., 
et al (2007). Effect of Enzyme Replacement Therapy with Imiglucerase on 
BMD in Type 1 Gaucher Disease. Journal of Bone and Mineral Research, 
22. 
West, B., Welch, K., & Galecki, A. (2007). Linear Mixed Models: A Practical 
Guide Using Statistical Software. Boca Raton: Chapman & Hall/CRC. 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
APPENDIX. Models of SPINEZ_FIRST 
This appendix contains 9 models of SPINEZ_FIRST derived using the RPART package 
from complete datasets, which are not concluded in 4.2.2 of the report.  
 
                                                                   
                                                                                                      
                                                                                                           
  
 
   
  
               
 
                                                                                       
 
              
 
    
                                                                                                                          
    
                                                                                                       
                                                                                                                                                                         
   
                             
<=101.5                 
Male 
>101.5                 
Female 
<=156.5        >156.5        
>52.5        <=52.5        
<=19.77              >19.77              
<=11 >11 
African American, 
Asian, Jewish (both 
Ashkenazi and 
Sephardic),   Jewish 
(neither Ashkenazi 
nor Sephardic), 
Multi-Ethnic                                                                                                      
Jewish-Sephardic, 
Arab, Hispanic, 
Caucasian, Jewish-
Ashkenazi, American 
Indian 
<=159.5 >159.5 
No Yes 
Americas, Asia, Pacific, S. Africa, Europe, 
USA Middle East 
REGION             
BISPHOS 
SEX 
ETHGRP 
AGEINF 
BMIB 
DOSAGE 
BIWEEK_FIRST_VISIT 
BIWEEK_FIRST_VISIT 
BIWEEK_FIRST_VISIT 
   N=81    N=32   N=49   N=54   N=20     N=44    N=87   N=102  N=66  N=202   N=144           
-1.717  -0.898 -1.683  -1.189 -0.313    -1.343   -0.359 -0.928   -1.438 -0.625   -0.387         
(1.058) (1.260)(0.831) (1.020) (1.515) (1.103) (1.185) (1.144) (1.132)(1.142) (1.223) 
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<=101.5 >101.5 
Male Female 
Yes No 
<=159.5 >159.5 
Middle East Americas, Asia, Pacific, S. Africa, Europe,USA 
<=21.0
2 
>21.02 
<=11 >11 
African American, 
Asian, Jewish (both 
Ashkenazi and 
Sephardic),   Jewish 
(neither Ashkenazi 
nor Sephardic), 
Multi-Ethnic                                                                                                      
Jewish-Sephardic, Arab, 
Hispanic, Caucasian, 
Jewish-Ashkenazi, 
American Indian 
REGION             
BISPHOS 
SEX 
ETHGRP 
AGEINF 
BMIB 
BIWEEK_FIRST_VISIT 
BIWEEK_FIRST_VISIT 
 N=81         N=32       N=49       N=78         N=44    N=87       N=153       N=221        N=144                          
-1.717       -0.898      -1.683    -0.964        -1.343   -0.359    -1.130        -0.658         -0.387              
(1.058)     (1.260)      (0.831)   (1.218)      (1.103)  (1.185)  (1.220)      (1.109)        (1.223) 
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<=21.5 >21.5 
Male Female 
<=101.5 >101.5 
Yes No 
Middle East 
Americas, Asia, Pacific, S. Africa, 
Europe, USA 
<=11 >11 
African American, 
Asian, Jewish (both 
Ashkenazi and 
Sephardic),   
Jewish (neither 
Ashkenazi nor 
Sephardic), Multi-
Ethnic                                                                                                      
Jewish-Sephardic, 
Arab, Hispanic, 
Caucasian, Jewish-
Ashkenazi, 
American Indian 
REGION             
BISPHOS 
SEX 
ETHGRP 
AGEINF 
AGEINF 
BIWEEK_FIRST_VISIT 
BIWEEK_FIRST_VISIT 
N=81       N=32        N=49      N=78       N=44      N=87         N=91          N=283        N=144                        
-1.717    -0.898      -1.683     -0.964     -1.343    -0.359       -1.233        -0.728         -0.387                         
(1.058)    (1.260)    (0.831)    (1.218)    (1.103)   (1.185)    (1.207)        (1.143)       (1.223) 
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<=159.5 >159.5 
<=11 >11 
<=19.77  >19.77 
<=101.5 >101.5 
Yes No 
>156.5 <=156.5 
>20.76 <=20.76 
Male 
>52.5 <=52.5 
African American, 
Asian, Jewish (both 
Ashkenazi and 
Sephardic),   Jewish 
(neither Ashkenazi 
nor Sephardic), 
Multi-Ethnic                                                                                                      
Jewish-Sephardic, 
Arab, Hispanic, 
Caucasian, Jewish-
Ashkenazi, 
American Indian 
Middle East Americas, Asia, Pacific, S. Africa, 
Europe, USA 
REGION             
BISPHOS 
SEX 
ETHGRP 
AGEINF 
BMIB 
DOSAGE 
BMIB 
BIWEEK_FIRST_VISIT 
BIWEEK_FIRST_VISIT 
Female 
  N=30    N=51    N=32    N=49     N=58    N=20   N=44     N=87    N=58   N=38   N=278   N=144                                
-2.291  -1.380  -0.898  -1.683   -1.189   -0.313  -1.343  -0.359  -0.996  -1.626 -0.715   -0.387      
(0.806) (1.050) (1.260) (0.831) (1.020)  (1.51) (1.103)   (1.185) (1.221)(1.084)(1.139)  (1.223) 
 
BIWEEK_FIRST_VISIT 
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<=21.02 >21.02 
<=159.5 >159.5 
No Yes 
Middle East 
Americas, Asia, Pacific, S. Africa, Europe, 
USA 
>11 <=11 
Male 
African American, 
Asian, Jewish 
(both Ashkenazi 
and Sephardic),   
Jewish (neither 
Ashkenazi nor 
Sephardic), Multi-
Ethnic                                                                                                      
Jewish-Sephardic, 
Arab, Hispanic, 
Caucasian, Jewish-
Ashkenazi, 
American Indian 
REGION             
BISPHOS 
SEX 
ETHGRP 
AGEINF 
BMIB 
Female 
N=81         N=32         N=49        N=78        N=44       N=87       N=153     N=221     N=144             
-1.717      -0.898       -1.683       -0.964      -1.343    -0.359       -1.130     -0.658      -0.387                
(1.058)     (1.260)      (0.831)      (1.218)     (1.103)   (1.185)    (1.220)    (1.109)    (1.223) 
 
BIWEEK_FIRST_VISIT 
BIWEEK_FIRST_VISIT 
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Female Male <=101.5 >101.5 
<=19.23 >19.23 
<=11 >11 
<=159.5 >159.5 
Yes No 
Middle East Americas, Asia, Pacific, S. Africa, Europe, USA 
African American, 
Asian, Jewish (both 
Ashkenazi and 
Sephardic),   Jewish 
(neither Ashkenazi 
nor Sephardic), 
Multi-Ethnic                                                                                                      
Jewish-Sephardic, 
Arab, Hispanic, 
Caucasian, Jewish-
Ashkenazi, 
American Indian 
REGION             
BISPHOS 
SEX 
ETHGRP 
AGEINF 
BMIB 
 N=81       N=32         N=49        N=78         N=44         N=87         N=89         N=285       N=144    
-1.717     -0.898       -1.683      -0.964        -1.343       -0.359       -1.314       -0.706        -0.387    
(1.058)    (1.260)      (0.831)     (1.218)       (1.103)      (1.185)     (1.151)      (1.150)      (1.223)               
BIWEEK_FIRST_VISIT 
BIWEEK_FIRST_VISIT 
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>101.5 <=101.5 
Male           Female         
Europe 
<=22.84 >22.84 
<=11 >11                   
<=159.5 >159.5 
No Yes 
Middle East Americas, Asia, Pacific, S. Africa, Europe, USA 
Middle East, 
Americas, Asia, 
Pacific, S.Africa, 
USA                 
African 
American, 
Asian, Jewish 
(both 
Ashkenazi and 
Sephardic),   
Jewish (neither 
Ashkenazi nor 
Sephardic), 
Multi-Ethnic                                                                                                      
Jewish-
Sephardic, Arab, 
Hispanic, 
Caucasian, 
Jewish-
Ashkenazi, 
American Indian 
REGION             
BISPHOS 
SEX 
ETHGRP 
AGEINF 
BMIB 
REGION             
BIWEEK_FIRST_VISIT 
BIWEEK_FIRST_VISIT 
N=81     N=32    N=49     N=14     N=64            N=44     N=87      N=200    N=174   N=144 
-1.717   -0.898  -1.683   -1.800   -0.781          -1.343    -0.359    -1.055    -0.617   - 0.387 
(1.058)  (1.260)  (0.831) (0.776) (1.225)        (1.103)  (1.185)   (1.212)   (1.094)  (1.223)  
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>101.5 
    
<=101.5 
Europe 
Male Female 
<=21.02 >21.02 
<=11 >11 
<=159.5 >159.5 
Yes No 
Middle East 
Americas, Asia, Pacific, S. Africa, 
Europe, USA 
African American, 
Asian, Jewish (both 
Ashkenazi and 
Sephardic),   Jewish 
(neither Ashkenazi 
nor Sephardic), 
Multi-Ethnic                                                                                                      
Jewish-
Sephardic, Arab, 
Hispanic, 
Caucasian, 
Jewish-
Ashkenazi, 
American Indian 
Middle East, 
Americas, Asia, 
Pacific, S.Africa, 
USA                 
REGION             
BISPHOS 
SEX BIWEEK_FIRST 
ETHGRP 
AGEINF 
BMIB 
REGION             
BIWEEK_FIRST_VISIT 
 N=81       N=32      N=49      N=14      N=64        N=44       N=87      N=153      N=216    N=144             
-1.717      -0.898    -1.683    -1.800    -0.781     -1.343       -0.359    -1.130      -0.657    -0.387      
(1.058)    (1.260)   (0.831)   (0.776)   (1.225)     (1.103)    (1.185)   (1.220)    (1.120)   (1.223) 
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>101.5 <=101.5 
Female Male 
<=21.2 >21.2 
>159.5 <=159.5 
Yes No 
Middle East Americas, Asia, Pacific, S. Africa, Europe, 
USA 
<=11 >11 
African American, 
Asian, Jewish (both 
Ashkenazi and 
Sephardic),   Jewish 
(neither Ashkenazi 
nor Sephardic), 
Multi-Ethnic                                                                                                      
Jewish-Sephardic, Arab, 
Hispanic, Caucasian, 
Jewish-Ashkenazi, 
American Indian 
REGION             
BISPHOS 
SEX 
ETHGRP 
AGEINF 
BMIB 
BIWEEK_FIRST_VISIT 
BIWEEK_FIRST_VISIT 
 N=81    N=32      N=49     N=78      N=44               N=87     N=168    N=206    N=144               
-1.717 -0.898    -1.683   -0.964    -1.343              -0.359   -1.128     -0.625     -0.387 
(1.058) (1.260)  (0.831) (1.218)   (1.103)             (1.185) (1.163)    (1.142)   (1.223) 
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